0001558370-21-014220 10-Q 59 20210930 20211103 20211103 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 10-Q 34 001-39202 211374014 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 10-Q 1 anvs-20210930x10q.htm 10-Q
0.350.151.150.61809910368715547466443611340080991036871554746644361134000.350.151.150.61NYSENon-accelerated Filer0.00010000081005700001477845--12-312021Q3false689160820001477845anvs:SeriesaRedeemableConvertiblePreferredStockMember2020-03-310001477845anvs:Series1RedeemableConvertiblePreferredStockMember2020-03-310001477845anvs:SeriesaRedeemableConvertiblePreferredStockMember2019-12-310001477845anvs:Series1RedeemableConvertiblePreferredStockMember2019-12-310001477845us-gaap:CommonStockMember2021-07-012021-09-300001477845us-gaap:CommonStockMember2020-04-012020-06-300001477845us-gaap:CommonStockMember2020-07-012020-09-300001477845us-gaap:RetainedEarningsMember2021-09-300001477845us-gaap:AdditionalPaidInCapitalMember2021-09-300001477845us-gaap:RetainedEarningsMember2021-06-300001477845us-gaap:AdditionalPaidInCapitalMember2021-06-3000014778452021-06-300001477845us-gaap:RetainedEarningsMember2021-03-310001477845us-gaap:AdditionalPaidInCapitalMember2021-03-3100014778452021-03-310001477845us-gaap:RetainedEarningsMember2020-12-310001477845us-gaap:AdditionalPaidInCapitalMember2020-12-310001477845us-gaap:RetainedEarningsMember2020-09-300001477845us-gaap:AdditionalPaidInCapitalMember2020-09-300001477845us-gaap:RetainedEarningsMember2020-06-300001477845us-gaap:AdditionalPaidInCapitalMember2020-06-3000014778452020-06-300001477845us-gaap:RetainedEarningsMember2020-03-310001477845us-gaap:AdditionalPaidInCapitalMember2020-03-3100014778452020-03-310001477845us-gaap:RetainedEarningsMember2019-12-310001477845us-gaap:AdditionalPaidInCapitalMember2019-12-310001477845us-gaap:CommonStockMember2021-09-300001477845us-gaap:CommonStockMember2021-06-300001477845us-gaap:CommonStockMember2021-03-310001477845us-gaap:CommonStockMember2020-12-310001477845us-gaap:CommonStockMember2020-09-300001477845us-gaap:CommonStockMember2020-06-300001477845us-gaap:CommonStockMember2020-03-310001477845us-gaap:CommonStockMember2019-12-310001477845us-gaap:CommonStockMemberanvs:SecondaryPublicOfferingMember2021-05-260001477845us-gaap:CommonStockMemberanvs:InitialPublicOfferingAndOverAllotmentOptionMember2020-01-310001477845anvs:PreviousPlansMember2020-01-310001477845anvs:EquityIncentivePlan2019Member2021-06-010001477845anvs:EquityIncentivePlan2019Member2021-05-310001477845us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001477845us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001477845us-gaap:EmployeeStockOptionMember2020-07-012020-09-300001477845us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001477845us-gaap:CommonStockMemberanvs:SecondaryPublicOfferingMember2021-05-262021-05-260001477845us-gaap:CommonStockMemberanvs:InitialPublicOfferingAndOverAllotmentOptionMember2020-01-312020-01-310001477845us-gaap:RetainedEarningsMember2021-07-012021-09-300001477845us-gaap:RetainedEarningsMember2021-04-012021-06-300001477845us-gaap:RetainedEarningsMember2021-01-012021-03-310001477845us-gaap:RetainedEarningsMember2020-07-012020-09-300001477845us-gaap:RetainedEarningsMember2020-04-012020-06-300001477845us-gaap:RetainedEarningsMember2020-01-012020-03-310001477845us-gaap:ConvertibleDebtMember2019-01-012019-12-310001477845anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember2021-09-300001477845anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember2020-12-310001477845us-gaap:ConvertibleDebtMemberanvs:RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMembersrt:DirectorMember2019-03-310001477845us-gaap:ConvertibleDebtMember2019-03-310001477845anvs:UnderwritersWarrantsMember2021-09-300001477845anvs:UnderwritersWarrantsMember2020-12-3100014778452020-09-3000014778452019-12-310001477845us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001477845us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001477845us-gaap:WarrantMember2021-01-012021-09-300001477845us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001477845us-gaap:WarrantMember2020-01-012020-06-300001477845us-gaap:EmployeeStockOptionMember2020-01-012020-06-300001477845us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-3000014778452021-07-012021-09-300001477845us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000014778452021-04-012021-06-3000014778452021-01-012021-03-310001477845us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001477845us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-3000014778452020-04-012020-06-3000014778452021-11-0100014778452020-01-012020-12-310001477845anvs:SeriesaRedeemableConvertiblePreferredStockMember2020-01-312020-01-310001477845anvs:Series1RedeemableConvertiblePreferredStockMember2020-01-312020-01-310001477845anvs:SeriesaRedeemableConvertiblePreferredStockMember2020-01-012020-03-310001477845anvs:Series1RedeemableConvertiblePreferredStockMember2020-01-012020-03-310001477845us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001477845us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100014778452020-01-012020-03-310001477845us-gaap:CommonStockMember2021-04-012021-06-300001477845us-gaap:CommonStockMember2021-01-012021-03-310001477845us-gaap:ConvertibleDebtMemberanvs:RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMembersrt:DirectorMemberus-gaap:CommonStockMember2020-01-312020-01-310001477845us-gaap:CommonStockMemberus-gaap:IPOMember2020-01-312020-01-310001477845us-gaap:CommonStockMember2020-01-012020-03-310001477845us-gaap:ConvertibleDebtMemberanvs:RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember2019-03-012019-03-310001477845anvs:UnderwritersWarrantsMember2020-01-310001477845srt:ExecutiveOfficerMember2021-09-300001477845anvs:HorizonTherapeuticsPlcMemberanvs:LicenseAgreementTermsAmendedMay2012Member2021-01-012021-09-300001477845anvs:HorizonTherapeuticsPlcMemberus-gaap:LicenseAgreementTermsMember2008-11-012008-11-300001477845anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember2021-07-012021-09-300001477845anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember2021-01-012021-09-300001477845anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember2020-07-012020-09-3000014778452020-07-012020-09-300001477845anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember2020-01-012020-09-300001477845anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember2019-09-3000014778452021-01-012021-09-300001477845anvs:UnderwritersWarrantsMember2021-01-012021-09-300001477845us-gaap:ConvertibleDebtMember2019-03-012019-03-3100014778452020-01-012020-09-3000014778452020-01-310001477845anvs:HorizonTherapeuticsPlcMemberanvs:LicenseAgreementTermsAmendedMay2012Member2021-09-300001477845anvs:HorizonTherapeuticsPlcMemberanvs:LicenseAgreementTermsAmendedMay2012Member2020-12-3100014778452021-09-3000014778452020-12-31iso4217:USDxbrli:sharesxbrli:pureanvs:itemanvs:Voteiso4217:USDxbrli:sharesanvs:lawsuit

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

COMMISSION FILE NUMBER 001-39202

Annovis Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware

26-2540421

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

1055 Westlakes Drive, Suite 300

Berwyn, PA 19312

(Address of registrant’s principal executive offices)

(610727-3913

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

    

Trading Symbol

    

Name of Each Exchange on Which Registered

Common Stock, par value $0.0001 per share

ANVS

NYSE American

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  No.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  No.

The number of outstanding shares of the registrant’s common stock as of November 1, 2021 was: 8,100,570.

ANNOVIS BIO, INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED SEPTEMBER 30, 2021

PART I – FINANCIAL INFORMATION

   

Page

Item 1.

Financial Statements

3

Balance Sheets as of September 30, 2021 (Unaudited) and December 31, 2020

3

Statements of Operations for the Three and Nine Months Ended September 30, 2021 and 2020 (Unaudited)

4

Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Three and Nine Months Ended September 30, 2021 and 2020 (Unaudited)

5

Statements of Cash Flows for the Nine Months Ended September 30, 2021 and 2020 (Unaudited)

6

Notes to Financial Statements (Unaudited)

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

16

Item 3.

Quantitative and Qualitative Disclosure About Market Risk

21

Item 4.

Controls and Procedures

21

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

22

Item 1A.

Risk Factors

22

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

22

Item 3.

Defaults Upon Senior Securities

22

Item 4.

Mine Safety Disclosures

22

Item 5.

Other Information

22

Item 6.

Exhibits

23

Signatures

24

2

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements

Annovis Bio, Inc.

Balance Sheets

    

September 30, 

December 31, 

    

2021

    

2020

(unaudited)

Assets

 

  

 

  

Current assets:

 

  

 

  

Cash and cash equivalents

$

47,455,334

$

8,074,658

Prepaid expenses and other current assets

 

195,156

 

44,676

Total current assets

 

47,650,490

 

8,119,334

Total assets

$

47,650,490

$

8,119,334

Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity

 

  

 

  

Current liabilities:

 

 

  

Accounts payable

$

289,742

$

341,856

Accrued expenses

 

830,859

 

236,524

Total current liabilities

 

1,120,601

 

578,380

Total liabilities

 

1,120,601

 

578,380

Commitments and contingencies (Note 8)

 

  

 

  

Stockholders’ equity:

 

  

 

  

Preferred stock - $0.0001 par value, 2,000,000 shares authorized, and 0 shares issued and outstanding

Common stock - $0.0001 par value, 35,000,000 shares authorized, and 8,100,570 and 6,891,608 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively

 

810

 

689

Additional paid-in capital

 

69,340,645

 

21,779,340

Accumulated deficit

 

(22,811,566)

 

(14,239,075)

Total stockholders’ equity

 

46,529,889

 

7,540,954

Total liabilities and stockholders’ equity

$

47,650,490

$

8,119,334

See accompanying notes to financial statements.

3

Annovis Bio, Inc.

Statements of Operations

(unaudited)

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2021

    

2020

    

2021

    

2020

Operating expenses:

  

 

  

  

 

  

Research and development

$

1,380,801

$

718,898

$

5,594,886

$

1,641,822

General and administrative

 

1,472,969

 

884,859

 

3,022,244

 

3,088,726

Total operating expenses

 

2,853,770

 

1,603,757

 

8,617,130

 

4,730,548

Operating loss

 

(2,853,770)

 

(1,603,757)

 

(8,617,130)

 

(4,730,548)

Other income (expense):

 

  

 

  

 

  

 

  

Change in fair value of derivative liability

 

 

 

 

(26,500)

Interest income, net

 

5,554

 

10,500

 

7,885

 

47,012

Grant income

 

 

586,903

 

36,754

 

952,602

Total other income (expense)

 

5,554

 

597,403

 

44,639

 

973,114

Loss before income taxes

 

(2,848,216)

 

(1,006,354)

 

(8,572,491)

 

(3,757,434)

Income tax expense (benefit)

 

 

 

 

Net loss

$

(2,848,216)

$

(1,006,354)

$

(8,572,491)

$

(3,757,434)

Basic and diluted loss per common share

$

(0.35)

$

(0.15)

$

(1.15)

$

(0.61)

Weighted average number of common shares outstanding, basic and diluted

 

8,099,103

 

6,871,554

 

7,466,443

 

6,113,400

See accompanying notes to financial statements.

4

Annovis Bio, Inc.

Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(unaudited)

    

Redeemable Convertible Preferred Stock

    

Stockholders’ Equity (Deficit)

Total

Additional

Stockholders’

Series A

Series A-1

Common Stock

Paid-In

Accumulated

Equity

    

Shares

    

Amount

    

Shares

Amount

    

    

Shares

    

Amount

    

Capital

    

Deficit

    

(Deficit)

Three and Nine Months Ended September 30, 2021

Balance, December 31, 2020

 

$

 

$

 

6,891,608

$

689

$

21,779,340

$

(14,239,075)

$

7,540,954

Exercise of stock options

 

 

 

 

 

3,868

 

1

 

3,016

 

 

3,017

Exercise of warrants

 

 

 

 

 

51,644

 

5

 

(5)

 

 

Share-based compensation expense

 

 

 

 

 

23,977

23,977

Net loss

 

 

 

 

 

 

 

 

(3,199,673)

 

(3,199,673)

Balance, March 31, 2021

 

$

 

$

 

6,947,120

$

695

$

21,806,328

$

(17,438,748)

$

4,368,275

Issuance of common stock, net of issuance costs

1,000,000

100

46,668,313

46,668,413

Exercise of stock options

 

 

 

 

141,532

 

14

 

92,071

 

 

92,085

Exercise of warrants

 

 

 

 

 

2,280

Share-based compensation expense

 

 

 

 

 

7,992

7,992

Net loss

 

 

 

 

 

 

 

(2,524,602)

 

(2,524,602)

Balance, June 30, 2021

$

$

8,090,932

$

809

$

68,574,704

$

(19,963,350)

$

48,612,163

Issuance costs

 

(20,000)

(20,000)

Exercise of stock options

 

 

 

 

9,638

 

1

 

(1)

 

 

Share-based compensation expense

 

 

 

 

785,942

785,942

Net loss

 

 

 

 

(2,848,216)

(2,848,216)

Balance, September 30, 2021

$

$

8,100,570

$

810

$

69,340,645

$

(22,811,566)

$

46,529,889

Three and Nine Months Ended September 30, 2020

Balance, December 31, 2019

5,133,159

$

6,509,303

 

630,722

$

567,649

 

282,614

$

28

$

200,600

$

(8,777,028)

$

(8,576,400)

Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering

 

(5,133,159)

 

(6,509,303)

 

(630,722)

 

(567,649)

 

4,117,089

 

412

 

7,076,540

 

 

7,076,952

Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering

 

 

 

 

 

118,470

 

12

 

672,512

 

 

672,524

Issuance of common stock in initial public offering, net of issuance costs

 

 

 

2,300,000

230

11,955,565

11,955,795

Exercise of stock options

 

 

 

 

 

27,286

 

3

 

4,603

 

 

4,606

Net loss

 

 

 

 

 

 

 

 

(441,590)

 

(441,590)

Balance, March 31, 2020

 

$

 

$

 

6,845,459

$

685

$

19,909,820

$

(9,218,618)

$

10,691,887

Exercise of stock options

 

 

 

 

21,149

 

2

 

4,609

 

 

4,611

Share-based compensation expense

 

 

 

 

 

1,111,272

1,111,272

Net loss

 

 

 

 

 

 

 

(2,309,490)

 

(2,309,490)

Balance, June 30, 2020

$

$

6,866,608

$

687

$

21,025,701

$

(11,528,108)

$

9,498,280

Issuance of common stock to consultants and advisors

 

 

 

5,000

21,950

21,950

Share-based compensation expense

 

 

 

 

607,067

607,067

Net loss

 

 

 

 

(1,006,354)

(1,006,354)

Balance, September 30, 2020

$

$

6,871,608

$

687

$

21,654,718

$

(12,534,462)

$

9,120,943

See accompanying notes to financial statements.

5

Annovis Bio, Inc.

Statements of Cash Flows

(unaudited)

Nine Months Ended September 30, 

2021

2020

Cash flows from operating activities:

  

 

  

Net loss

$

(8,572,491)

$

(3,757,434)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

Amortization of deferred financing fees

 

 

129

Amortization of debt discount

 

 

396

Share-based compensation expense, including stock issued to consultants and advisors

 

817,911

 

1,740,289

Change in fair value of derivative liability

 

 

26,500

Changes in operating assets and liabilities:

 

 

Grant receivable

 

 

310,123

Prepaid expenses and other current assets

 

(150,480)

 

(125,863)

Accounts payable

 

(52,114)

 

(897,739)

Accrued expenses

 

594,335

 

(501,275)

Net cash used in operating activities

 

(7,362,839)

 

(3,204,874)

Cash flows from financing activities:

 

  

 

  

Proceeds from issuance of common stock, net of issuance costs

 

46,648,413

 

12,034,406

Proceeds from exercise of stock options

 

95,102

 

9,217

Net cash provided by financing activities

 

46,743,515

 

12,043,623

Net increase in cash and cash equivalents

 

39,380,676

 

8,838,749

Cash and cash equivalents, beginning of period

 

8,074,658

 

1,858

Cash and cash equivalents, end of period

$

47,455,334

$

8,840,607

Supplemental disclosure of non-cash financing activities:

 

  

 

  

Conversion of redeemable convertible preferred stock to common stock

$

$

7,076,952

Conversion of convertible promissory notes, including embedded derivative, to common stock

$

$

672,524

See accompanying notes to financial statements.

6

Table of Contents

Annovis Bio, Inc.

Notes to Financial Statements

(Unaudited)

(1) Nature of Business and Liquidity

Annovis Bio, Inc. (the “Company” or “Annovis”) was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”) and Down syndrome patients with AD (“DS-AD”). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company’s lead compound, ANVS401, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.

Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.

The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of equity securities.

The Company closed its initial public offering (the “IPO”) on January 31, 2020, pursuant to which it sold a total of 2,300,000 shares of common stock at an initial offering price of $6.00 per share for total gross proceeds of approximately $13.8 million. The net proceeds of the IPO were approximately $12.0 million after deducting underwriting discounts and issuance costs paid by the Company. In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. Upon the closing of the IPO, outstanding redeemable convertible preferred stock and convertible promissory notes converted into shares of Company common stock totaling 4,117,089 and 118,470, respectively. The Company’s common stock trades on the NYSE American under the ticker symbol “ANVS”.

On May 26, 2021, the Company closed an underwritten public offering of 1,000,000 shares of its common stock at an offering price of $50.00 per share, for gross proceeds of $50.0 million. The net proceeds of the offering were approximately $46.6 million, after deducting underwriting discounts and issuance costs paid or payable by the Company.

As of the date these financial statements are issued, management believes that the current cash and cash equivalents are sufficient to fund operations and capital requirements for at least the next 12 months, including the remaining costs of its Phase 2a clinical trial in AD and PD (the “AD/PD Trial”) which finished treating patients in the third quarter of 2021 and a potential Phase 3 trial in AD, PD, or DS-AD. In order to fund additional planned Phase 3 trials, however, the Company will need to raise additional capital. There is no assurance that such financing will be available when needed or on acceptable terms.

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation of Interim Unaudited Financial Statements

The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial

7

position of Annovis at September 30, 2021, and its results of operations and its cash flows for the three and nine months ended September 30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.

Significant items subject to such estimates and assumptions include share-based compensation expense, the valuation of the derivative liability and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.

(c) Basic and Diluted Net Income (Loss) per Share

Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes, warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.

(d) Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.

(e)  Issuance Costs Associated with Equity Issuances

Issuance costs incurred in connection with the Company’s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed.

(f) Fair Value of Financial Instruments

The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature.

8

(g) Research and Development

Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.

(h) Grant Income

Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.

(i) Share-Based Compensation

Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.

Determining the appropriate fair value of share-based awards requires the use of subjective assumptions including, in the case of stock options, the expected life of the option and expected share price volatility. The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.

The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

(j) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2021 and December 31, 2020, the Company has recorded a full valuation allowance against its deferred tax assets.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at September 30, 2021 or December 31, 2020.

9

(k) Recent Accounting Pronouncements

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on the Company’s financial statements.

(3) Fair Value Measurements

The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:

    

    

Fair Value Measurement at

September 30, 2021

Carrying Value

Level 1

Level 2

Level 3

Cash and cash equivalents

$

47,455,334

$

47,455,334

$

$

    

    

Fair Value Measurement at

December 31, 2020

Carrying Value

Level 1

Level 2

Level 3

Cash and cash equivalents

$

8,074,658

$

8,074,658

$

$

(4) Grant Receivable

In September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of long-term chronic toxicology studies of ANVS401 in rats and dogs. The Company began the long-term chronic toxicology studies in November 2019. The Company recognized grant income of $0 and $586,903 for the three months ended September 30, 2021 and 2020, respectively, and $36,754 and $952,602 for the nine months ended September 30, 2021 and 2020, respectively, in connection with the NIH grant. The Company received payments under the grant of $36,754 and $1,262,725 during the nine months ended September 30, 2021 and 2020, respectively. The Company

10

recorded a grant receivable of $0 as of September 30, 2021 and December 31, 2020, and had no unreimbursed, eligible costs incurred under the grant. As of September 30, 2021, there were no remaining funds available under the grant.

(5) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

    

September 30, 

December 31, 

2021

2020

Prepaid insurance

$

121,501

$

26,542

Prepaid expenses

 

63,790

 

11,690

Security deposit

 

9,865

 

6,444

$

195,156

$

44,676

(6) Accrued Expenses

Accrued expenses consisted of the following:

    

September 30, 

December 31, 

2021

2020

Payroll and related benefits

$

243,684

$

16,493

Accrued professional and clinical fees

 

548,842

 

216,198

Accrued license payments

 

38,333

 

3,833

$

830,859

$

236,524

See Note 8 for further detail on the accrued license payments.

(7) Convertible Promissory Notes

In March 2019, the Company issued convertible promissory notes (the “Notes”) to various investors in the aggregate principal amount of $530,000 with a stated interest rate of 8% compounded annually. On issuance, the Company recognized a discount associated with the Notes related to the fair value of an embedded derivative liability reflecting the share-settlement feature providing for the conversion of the Notes at a 20% discount to the price of the shares issued in a qualified financing. The Company estimated the fair value of the derivative liability using a probability-weighted approach at issuance, as of the end of each reporting period and immediately prior to the closing of the IPO. The change in the fair value of the derivative liability was reflected in the statements of operations. The Company amortized deferred financing fees and debt discount over the term of the Notes as additional interest expense using the effective interest method. The effective interest rate on the Notes was 9.8%. The Company made no cash payments for interest on the Notes. On January 31, 2020, the Company closed its IPO and in accordance with the terms of the Notes, the outstanding Notes plus accrued interest converted into 118,470 shares of Company common stock.

(8) Commitments and Contingencies

(a) Leases

The Company leases its office facilities under a month-to-month operating lease. Total rental expense was $13,410 and $10,394 for the three months ended September 30, 2021 and 2020, respectively and $36,600 and $31,209 for the nine months ended September 30, 2021 and 2020, respectively.

11

(b) License Agreement

The Company previously licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics from a subsidiary of Horizon Therapeutics, PLC (the “Licensor”). Under the license agreement, the Company pays a minimum annual commitment of $46,000 and is required to make milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Company has paid to the Licensor all annual fees through November 2020. At September 30, 2021 and December 31, 2020, the Company had accrued $38,333 and $3,833, respectively, in license payments under the term of this license, included in accrued liabilities. No milestones have been achieved as of September 30, 2021. The Licensor also granted the Company a buy-out option which may be exercised at any time during the term of the agreement at increasing amounts based on the achievement of certain milestones. The Company has the right to terminate the agreement at any time by giving 90 days advance notice subject to the payment of any amounts due under the agreement at that time. Expenses related to the license agreement are recognized in general and administrative expense in the statements of operations.

In July 2021, the Company gave notice to the Licensor of its termination of the license agreement.

(c) Employment Agreements

The maximum aggregate severance payments under the Company’s employment agreements with its executive officers are approximately $930,000.

(d) Litigation

The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.

During the three months ended September 30, 2021, two securities class action complaints were filed against the Company and its executive officers following disclosure of interim results from the AD/PD Trial. Both complaints were subsequently voluntarily dismissed without prejudice by the plaintiffs.

(e) Risks and Uncertainties

The extent to which the COVID-19 pandemic could have a material impact on the Company’s current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. Management continues to evaluate the potential impact. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

(9) Redeemable Convertible Preferred Stock and Stockholders’ Equity

(a) Overview

In connection with the closing of the Company’s IPO on January 31, 2020, the then-outstanding 5,133,159 shares of Series A and 630,722 shares of Series A-1 redeemable convertible preferred stock converted into an aggregate of 4,117,089 shares of Company common stock.

The Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020 to authorize the issuance of two classes of stock to be designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 37,000,000, each with a par value of $0.0001 per share. Of these shares, 35,000,000 shall be common stock and 2,000,000 shall be preferred stock.

12

(b) Common Stock

1.           Dividends

Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.

2.           Liquidation

Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.

3.           Voting

The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.

(c) Preferred Stock

Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of September 30, 2021 or December 31, 2020.

(d) Warrants

In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which was 125% of the initial public offering price. The warrants have a five-year term and are exercisable commencing January 29, 2021. During the nine months ended September 30, 2021, 97,600 of the warrants were tendered to the Company by the holders pursuant to cashless exercises. As of September 30, 2021 and December 31, 2020, 2,400 and 100,000 of the warrants were outstanding, respectively. The Company accounts for the warrants as a component of stockholders’ equity.

(10) Share-Based Compensation

Effective upon the closing of the Company’s IPO on January 31, 2020, the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective, succeeding the Company’s previous plan (see Note 1). As of the effective date of the 2019 Plan, the previous plan had 352,282 options outstanding 2019 Plan and no new awards may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 shares to 2,000,000. As of September 30, 2021, 1,084,464 shares were available for future grants.

During the nine months ended September 30, 2021, the Company granted options to purchase 84,200 shares of common stock at an exercise price of $102.85 per share to employees, members of its board of directors and consultants. Under the grant agreements, all of the options vest in substantially equal quarterly installments over two years and have a 10-year term. The options granted during the nine months ended September 30, 2021 were valued using the Black Scholes option pricing model using the following assumptions: (i) expected term of 5.6 years; (ii) risk free interest rate of 0.87%; (iii) expected volatility of 104.0%; and (iv) dividend yield of 0.0%. The weighted-average grant date fair value of options issued by the Company during the nine months ended September 30, 2021 was $80.76 per share.

Share-based compensation expense, including the fair value of stock awards to consultants and advisors, for the three months ended September 30, 2021 and 2020 was $785,942 and $629,017, respectively, and for the nine months ended September 30, 2021 and 2020 was $817,911 and $1,740,289, respectively. As of September 30, 2021, there were

13

1,035,853 options outstanding, of which 951,653 were vested and exercisable. As of December 31, 2020, there were 1,111,466 options outstanding, of which 1,061,466 were vested and exercisable.

(11) Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2021

    

2020

    

2021

    

2020

Numerator:

 

  

 

  

  

 

  

Net loss

$

(2,848,216)

$

(1,006,354)

$

(8,572,491)

$

(3,757,434)

Denominator:

 

  

 

  

 

  

 

  

Weighted-average common shares outstanding, basic and diluted

 

8,099,103

 

6,871,554

 

7,466,443

 

6,113,400

Net loss per share, basic and diluted

$

(0.35)

$

(0.15)

$

(1.15)

$

(0.61)

The Company reported a net loss for the three and nine months ended September 30, 2021 and 2020, therefore, the basic and diluted net loss per share are the same in the respective period because the inclusion of potential common shares would have an anti-dilutive effect. Potential shares of common stock that are excluded from the computation of diluted weighted-average shares outstanding are as follows:

September 30, 

    

2021

    

2020

Stock options

1,035,853

1,113,847

Warrants

 

2,400

 

100,000

In addition, common shares issuable upon the conversion of the Notes were excluded for all periods in which the Notes were outstanding.

(12) Income Taxes

The Company’s income tax benefit (expense) was $0 for the three and nine months ended September 30, 2021 and 2020. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss (“NOL”) that would have been recognized in the three and nine months ended September 30, 2021 and 2020 was offset by changes in the valuation allowance.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.

Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.

14

As of September 30, 2021, and December 31, 2020, the Company had not recorded any liability for uncertain tax positions, accrued interest or penalties thereon, and no amounts have been recognized in the Company’s statements of operations.

(13) Related-Party Transactions

As discussed in Note 7, in March 2019 the Company issued Notes in the aggregate principal amount of $530,000. Three of the Company’s directors purchased an aggregate of $305,000 of the Notes. On January 31, 2020, the Company closed its IPO, and the outstanding Notes plus accrued interest held by directors converted into 71,429 shares of Company common stock.

15

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” and or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:

our business strategies;
the timing of regulatory submissions;
our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;
risks relating to the timing and costs of clinical trials and the timing and costs of other expenses;
risks related to market acceptance of products;
risks associated with our reliance on third-party organizations;
our competitive position;
assumptions regarding the size of the available market, product pricing and timing of commercialization of our product candidates;
our intellectual property position and our ability to maintain and protect our intellectual property rights;
our results of operations, financial condition, liquidity, prospects, and growth strategies;
our cash needs and financing plans;
the industry in which we operate; and
the trends that may affect the industry or us.

You should refer to Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2020 for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Those factors are updated, as applicable, in “Factors that May Affect Future Results” below. As a result of the risks, uncertainties and assumptions described above and elsewhere, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the

16

significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to new information, actual results or changes in our expectations, except as required by law.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with: (i) the interim financial statements and related notes thereto which are included in this Quarterly Report on Form 10-Q; and (ii) our annual financial statements for the year ended December 31, 2020 which are included in our Annual Report on Form 10-K for the year ended December 31, 2020.

Company Overview

We are a clinical stage, drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”) and Down Syndrome patients with AD (“DS-AD”). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. Our lead compound, ANVS401, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of neurotoxic proteins—amyloid precursor protein APP/Aβ (“APP”), tau/phospho-tau (“tau”) and α-Synuclein (“αSYN”)—thereby impeding the toxic cascade. Human studies in four mildly cognitive impaired patients have shown that ANVS401 lowered the levels of neurotoxic proteins and inflammatory factors. In preclinical studies, lower neurotoxic protein levels led to improved axonal transport, reduced inflammation, lower nerve cell death and improved function.

In collaboration with the Alzheimer’s Disease Cooperative Study (“ADCS”) we are conducting a trial in 24 early AD patients (the “ADCS Trial”). Under an agreement with UC San Diego, where ADCS is located, we have contracted to provide study supplies at our cost but the remaining costs of the ADCS Trial are paid for by the National Institutes of Health (“NIH”). We are also conducting a Phase 2a clinical trial in 14 AD and 54 PD patients (the “AD/PD Trial”) which finished treating patients in August 2021. Both clinical trials are double-blind, placebo-controlled studies.

The extent to which the COVID-19 pandemic could have a material impact on our current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. We continue to evaluate the potential impact.

We have never been profitable and have incurred net losses since inception. Our accumulated deficit at September 30, 2021 was $22,811.6 thousand. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability.

17

Results of Operations

Operating expenses and other income (expense) were comprised of the following:

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

    

2021

    

2020

2021

    

2020

 

(in thousands)

(in thousands)

 

Operating expenses:

Research and development

$

1,380.8

    

$

718.9

$

5,594.9

    

$

1,641.8

    

General and administrative

 

1,473.0

 

884.9

 

3,022.2

 

3,088.7

Other income (expense):

Change in fair value of derivative liability

 

 

 

 

(26.5)

Interest income, net

 

5.6

 

10.5

 

7.9

 

47.0

Grant income

 

 

586.9

 

36.8

 

952.6

Three Months Ended September 30, 2021 and 2020

Research and Development Expenses

Research and development expenses increased by $661.9 thousand for the three months ended September 30, 2021 compared to the prior year period. The increase was primarily the result of an increase of $715.8 thousand in expenses related to our clinical trials. For the year ending December 31, 2021, we expect research and development expenses to be higher than the prior year as we complete our AD/PD Trial and commence the planning of a Phase 3 study.

General and Administrative Expenses

General and administrative expenses increased by $588.1 thousand for the three months ended September 30, 2021 compared to the prior year period. The increase was primarily the result of an increase in conference expenses, professional fees and recruiting expenses. We expect general and administrative expenses in 2021 will be higher as compared to 2020 due to increased personnel expenses.

Interest Income, Net

Interest income, net decreased $4.9 thousand for the three months ended September 30, 2021 compared to the prior year period. The decrease was primarily the result of lower interest rates compared to the prior year period.

Grant Income

Grant income decreased $586.9 thousand for the three months ended September 30, 2021 compared to the prior year period. The income relates to a grant from the NIH to reimburse the costs of our long-term toxicology studies in rats and dogs, which was substantially completed in 2020.

Nine months Ended September 30, 2021 and 2020

Research and Development Expenses

Research and development expenses increased by $3,953.1 thousand for the nine months ended September 30, 2021 compared to the prior year period. The increase was primarily the result of an increase of $3,800.6 thousand in expenses related to our clinical trials and an increase of $540.5 thousand in personnel expenses, including share-based compensation expense, partially offset by a decrease of $451.5 thousand in expenses related to our long-term toxicology studies. For the year ending December 31, 2021, we expect research and development expenses to be higher than the prior year as we complete our AD/PD Trial and commence the planning of a Phase 3 study.

18

General and Administrative Expenses

General and administrative expenses decreased by $66.5 thousand for the nine months ended September 30, 2021 compared to the prior year period. The decrease was primarily the result of a decrease in share-based compensation expense of $1,119.9 thousand, partially offset by an increase in accrued incentive compensation expense, conference expenses and an increase in recruiting expenses. We expect general and administrative expenses in 2021 will be higher as compared to 2020 due to increased personnel expenses.

Change in Fair Value of Derivative Liability

The derivative liability represents an embedded derivative in our convertible promissory notes which were issued in March 2019. At each balance sheet date, we estimated the fair value of the derivative liability and recognized any change in our statements of operations. The fair value of the derivative liability was adjusted to $132.5 thousand immediately prior to the closing of the IPO on January 31, 2020. Effective upon the closing of the IPO, the derivative liability was eliminated, and the amount was reclassified to additional paid-in capital on the balance sheet.

Interest Income, Net

Interest income, net decreased $39.1 thousand for the nine months ended September 30, 2021 compared to the prior year period. The decrease was primarily the result of lower interest rates compared to the prior year period.

Grant Income

Grant income decreased $915.8 thousand for the nine months ended September 30, 2021 compared to the prior year period. The income relates to a grant from the NIH to reimburse the costs of our long-term toxicology studies in rats and dogs, which was substantially completed in 2020.

Liquidity and Capital Resources

Since our inception in 2008, we have devoted most of our cash resources to research and development and general and administrative activities. We have financed our operations primarily with the proceeds from the sale of common stock, redeemable convertible preferred stock, and convertible promissory notes and funding from research grants. To date, we have not generated any revenues from the sale of products, and we do not anticipate generating any revenues from the sales of products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. As of September 30, 2021, our principal source of liquidity was our cash, which totaled $47,455.3 thousand.

Equity Financings

We closed our IPO on January 31, 2020, raising gross proceeds of $13,800.0 thousand and net proceeds of $12,034.4 thousand, after deducting underwriting discounts and commissions and issuance costs paid by us, in the nine months ended September 30, 2020.

We closed an equity offering on May 26, 2021, raising gross proceeds of $50,000.0 thousand and net proceeds of $46,648.4 thousand, after deducting underwriting discounts and commissions and issuance costs paid or payable by us, in the nine months ended September 30, 2021.

Debt Financings

In March 2019 we issued $530.0 thousand principal amount of convertible promissory notes. Upon the closing of our IPO on January 31, 2020, the outstanding convertible promissory notes plus accrued interest converted into 118,470 shares of our common stock at a 20% discount to the public offering price.

19

Cash Flows

The following table summarizes our cash flows from operating, investing and financing activities.

Nine Months Ended

September 30, 

    

2021

    

2020

(in thousands)

Statement of Cash Flows Data:

 

  

    

  

Total net cash provided by (used in):

 

  

 

  

Operating activities

$

(7,362.8)

$

(3,204.9)

Financing activities

 

46,743.5

 

12,043.6

Increase in cash and cash equivalents

$

39,380.7

$

8,838.7

Operating Activities

For the nine months ended September 30, 2021, cash used in operations increased $4,157.9 thousand compared to the same period in the prior year. The increase in cash used in operations was primarily the result of the ongoing costs of our AD/PD Trial.

We expect cash used in operating activities to increase in 2021 as compared to 2020 due to an expected increase in our operating losses associated with ongoing development of our product candidates, including our AD/PD Trial.

Financing Activities

Cash provided by financing activities was $46,743.5 thousand during the nine months ended September 30, 2021, attributable to net proceeds from our equity offering of approximately $46,648.4 thousand and proceeds from the exercise of stock options of $95.1 thousand.

Cash provided by financing activities was $12,043.6 thousand during the nine months ended September 30, 2020, attributable to net proceeds from our IPO of $12,034.4 thousand, and proceeds from the exercise of stock options of $9.2 thousand.

Funding Requirements

We expect that current cash and cash equivalents will be sufficient to fund our operations and capital requirements for at least the next 12 months. We believe that these available funds will be sufficient to complete our Phase 2a clinical trials for ANVS401 which finished treating patients in August 2021, and to complete a Phase 3 study in AD, PD, or DS-AD patients for this product candidate. However, it is difficult to predict our spending for our product candidates prior to obtaining FDA approval. Moreover, changing circumstances may cause us to expend cash significantly faster than we currently anticipate, and we may need to spend more cash than currently expected because of circumstances beyond our control.

To the extent that our capital resources are insufficient to meet our future operating and capital requirements, we will need to finance our cash needs through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. We have no committed external sources of funds. Additional equity or debt financing or collaboration and licensing arrangements may not be available on acceptable terms, if at all.

20

Contractual Obligations and Other Commitments

This item is not required for smaller reporting companies.

Factors that May Affect Future Results

You should refer to Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2020 for a discussion of important factors that may affect our future results.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined by applicable SEC regulations.

Discussion of Critical Accounting Policies and Significant Judgments and Estimates

The preparation of financial statements in conformity with GAAP requires us to use judgment in making certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in our financial statements and accompanying notes. Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations and require difficult, subjective and complex judgments by management in order to make estimates about the effect of matters that are inherently uncertain. During the three months ended September 30, 2021, there were no significant changes to our critical accounting policies from those described in our annual financial statements for the year ended December 31, 2020, which we included in our Annual Report on Form 10-K for the year ended December 31, 2020.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

This item is not required for smaller reporting companies.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as the end of the period covered by this Quarterly Report on Form 10-Q. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that the information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

(b) Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(f) and 15d-15(f) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

21

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition.

Item 1A. Risk Factors

This item is not required for smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

22

Item 6. Exhibits

Exhibit
Number

    

Description of Exhibit

 

3.1

Amended and Restated Certificate of Incorporation of the Registrant. (Incorporated by reference to Exhibit 3.1 to Form 8-K filed February 6, 2020.)

 

3.2

Amended and Restated Bylaws of the Registrant. (Incorporated by reference to Exhibit 3.2 to Form 8-K filed February 6, 2020.)

31.1

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

31.2

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

32.1

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

32.2

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Extension Labels Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

23

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Signature

    

Title

    

Date

 

 

 

/s/ MARIA MACCECCHINI

President and Chief Executive Officer (principal

November 3, 2021

Maria Maccecchini

executive officer)

 

 

 

/s/ JEFFREY MCGROARTY

Chief Financial Officer (principal financial and

November 3, 2021

Jeffrey McGroarty

accounting officer)

24

EX-31.1 2 anvs-20210930xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Maria Maccecchini, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Annovis Bio, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 3, 2021

/s/ Maria Maccecchini

Maria Maccecchini

President and Chief Executive Officer


EX-31.2 3 anvs-20210930xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jeffrey McGroarty, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Annovis Bio, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 3, 2021

/s/ Jeffrey McGroarty

Jeffrey McGroarty

Chief Financial Officer


EX-32.1 4 anvs-20210930xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Annovis Bio, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Maria Maccecchini, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 3, 2021

/s/ Maria Maccecchini

Maria Maccecchini

President and Chief Executive Officer


EX-32.2 5 anvs-20210930xex32d2.htm EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Annovis Bio, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey McGroarty, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 3, 2021

/s/ Jeffrey McGroarty

Jeffrey McGroarty

Chief Financial Officer


EX-101.SCH 6 anvs-20210930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Statements of Changes in Redeemable Convertible Preferred Stock link:presentationLink link:calculationLink link:definitionLink 00301 - Statement - Statements of Changes in Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Business and Liquidity link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Grant Receivable link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Convertible Promissory Notes link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of Business and Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Grant Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Convertible Promissory Notes (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Commitments and Contingencies - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Commitments and Contingencies - License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Commitments and Contingencies - Employment Agreements and Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Share-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 anvs-20210930_cal.xml EX-101.CAL EX-101.DEF 8 anvs-20210930_def.xml EX-101.DEF EX-101.LAB 9 anvs-20210930_lab.xml EX-101.LAB EX-101.PRE 10 anvs-20210930_pre.xml EX-101.PRE XML 11 anvs-20210930x10q_htm.xml IDEA: XBRL DOCUMENT 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2020-03-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2020-03-31 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2019-12-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2019-12-31 0001477845 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001477845 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001477845 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001477845 us-gaap:RetainedEarningsMember 2021-09-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001477845 us-gaap:RetainedEarningsMember 2021-06-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001477845 2021-06-30 0001477845 us-gaap:RetainedEarningsMember 2021-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001477845 2021-03-31 0001477845 us-gaap:RetainedEarningsMember 2020-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001477845 us-gaap:RetainedEarningsMember 2020-09-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001477845 us-gaap:RetainedEarningsMember 2020-06-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001477845 2020-06-30 0001477845 us-gaap:RetainedEarningsMember 2020-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001477845 2020-03-31 0001477845 us-gaap:RetainedEarningsMember 2019-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001477845 us-gaap:CommonStockMember 2021-09-30 0001477845 us-gaap:CommonStockMember 2021-06-30 0001477845 us-gaap:CommonStockMember 2021-03-31 0001477845 us-gaap:CommonStockMember 2020-12-31 0001477845 us-gaap:CommonStockMember 2020-09-30 0001477845 us-gaap:CommonStockMember 2020-06-30 0001477845 us-gaap:CommonStockMember 2020-03-31 0001477845 us-gaap:CommonStockMember 2019-12-31 0001477845 us-gaap:CommonStockMember anvs:SecondaryPublicOfferingMember 2021-05-26 0001477845 us-gaap:CommonStockMember anvs:InitialPublicOfferingAndOverAllotmentOptionMember 2020-01-31 0001477845 anvs:PreviousPlansMember 2020-01-31 0001477845 anvs:EquityIncentivePlan2019Member 2021-06-01 0001477845 anvs:EquityIncentivePlan2019Member 2021-05-31 0001477845 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001477845 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001477845 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001477845 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001477845 us-gaap:CommonStockMember anvs:SecondaryPublicOfferingMember 2021-05-26 2021-05-26 0001477845 us-gaap:CommonStockMember anvs:InitialPublicOfferingAndOverAllotmentOptionMember 2020-01-31 2020-01-31 0001477845 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001477845 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001477845 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001477845 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001477845 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001477845 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001477845 us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2021-09-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2020-12-31 0001477845 us-gaap:ConvertibleDebtMember anvs:RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember srt:DirectorMember 2019-03-31 0001477845 us-gaap:ConvertibleDebtMember 2019-03-31 0001477845 anvs:UnderwritersWarrantsMember 2021-09-30 0001477845 anvs:UnderwritersWarrantsMember 2020-12-31 0001477845 2020-09-30 0001477845 2019-12-31 0001477845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001477845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001477845 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001477845 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001477845 us-gaap:WarrantMember 2020-01-01 2020-06-30 0001477845 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001477845 2021-07-01 2021-09-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001477845 2021-04-01 2021-06-30 0001477845 2021-01-01 2021-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001477845 2020-04-01 2020-06-30 0001477845 2021-11-01 0001477845 2020-01-01 2020-12-31 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2020-01-31 2020-01-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2020-01-31 2020-01-31 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001477845 2020-01-01 2020-03-31 0001477845 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001477845 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001477845 us-gaap:ConvertibleDebtMember anvs:RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember srt:DirectorMember us-gaap:CommonStockMember 2020-01-31 2020-01-31 0001477845 us-gaap:CommonStockMember us-gaap:IPOMember 2020-01-31 2020-01-31 0001477845 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001477845 us-gaap:ConvertibleDebtMember anvs:RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember 2019-03-01 2019-03-31 0001477845 anvs:UnderwritersWarrantsMember 2020-01-31 0001477845 srt:ExecutiveOfficerMember 2021-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member 2021-01-01 2021-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember us-gaap:LicenseAgreementTermsMember 2008-11-01 2008-11-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2021-07-01 2021-09-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2021-01-01 2021-09-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2020-07-01 2020-09-30 0001477845 2020-07-01 2020-09-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2020-01-01 2020-09-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2019-09-30 0001477845 2021-01-01 2021-09-30 0001477845 anvs:UnderwritersWarrantsMember 2021-01-01 2021-09-30 0001477845 us-gaap:ConvertibleDebtMember 2019-03-01 2019-03-31 0001477845 2020-01-01 2020-09-30 0001477845 2020-01-31 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member 2021-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member 2020-12-31 0001477845 2021-09-30 0001477845 2020-12-31 iso4217:USD shares pure anvs:item anvs:Vote iso4217:USD shares anvs:lawsuit -0.35 -0.15 -1.15 -0.61 8099103 6871554 7466443 6113400 8099103 6871554 7466443 6113400 -0.35 -0.15 -1.15 -0.61 NYSE Non-accelerated Filer 0.0001 0 0 0 0 0 8100570 0001477845 --12-31 2021 Q3 false 6891608 2 10-Q true 2021-09-30 false 001-39202 Annovis Bio, Inc. DE 26-2540421 1055 Westlakes Drive, Suite 300 Berwyn PA 19312 610 727-3913 Common Stock, par value $0.0001 per share ANVS Yes Yes true true true false 8100570 47455334 8074658 195156 44676 47650490 8119334 47650490 8119334 289742 341856 830859 236524 1120601 578380 1120601 578380 0.0001 0.0001 2000000 2000000 0 0 0.0001 0.0001 35000000 35000000 8100570 6891608 810 689 69340645 21779340 -22811566 -14239075 46529889 7540954 47650490 8119334 1380801 718898 5594886 1641822 1472969 884859 3022244 3088726 2853770 1603757 8617130 4730548 -2853770 -1603757 -8617130 -4730548 -26500 5554 10500 7885 47012 586903 36754 952602 5554 597403 44639 973114 -2848216 -1006354 -8572491 -3757434 -2848216 -1006354 -8572491 -3757434 -0.35 -0.15 -1.15 -0.61 8099103 6871554 7466443 6113400 6891608 689 21779340 -14239075 7540954 3868 1 3016 3017 51644 5 -5 23977 23977 -3199673 -3199673 6947120 695 21806328 -17438748 4368275 1000000 100 46668313 46668413 141532 14 92071 92085 2280 7992 7992 -2524602 -2524602 8090932 809 68574704 -19963350 48612163 20000 20000 9638 1 -1 785942 785942 -2848216 -2848216 8100570 810 69340645 -22811566 46529889 5133159 6509303 630722 567649 282614 28 200600 -8777028 -8576400 5133159 6509303 630722 567649 4117089 412 7076540 7076952 118470 12 672512 672524 2300000 230 11955565 11955795 27286 3 4603 4606 -441590 -441590 0 0 0 0 6845459 685 19909820 -9218618 10691887 21149 2 4609 4611 1111272 1111272 -2309490 -2309490 6866608 687 21025701 -11528108 9498280 5000 21950 21950 607067 607067 -1006354 -1006354 6871608 687 21654718 -12534462 9120943 -8572491 -3757434 129 396 817911 1740289 -26500 -310123 150480 125863 -52114 -897739 594335 -501275 -7362839 -3204874 46648413 12034406 95102 9217 46743515 12043623 39380676 8838749 8074658 1858 47455334 8840607 7076952 672524 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(1) Nature of Business and Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis Bio, Inc. (the “Company” or “Annovis”) was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”) and Down syndrome patients with AD (“DS-AD”). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company’s lead compound, ANVS401, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has <span style="-sec-ix-hidden:Hidden_53VTBV6xCEuTSQFy7OES1A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">not</span></span> generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company closed its initial public offering (the “IPO”) on January 31, 2020, pursuant to which it sold a total of 2,300,000 shares of common stock at an initial offering price of $6.00 per share for total gross proceeds of approximately $13.8 million. The net proceeds of the IPO were approximately $12.0 million after deducting underwriting discounts and issuance costs paid by the Company. In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. Upon the closing of the IPO, outstanding redeemable convertible preferred stock and convertible promissory notes converted into shares of Company common stock totaling 4,117,089 and 118,470<span style="white-space:pre-wrap;">, respectively. The Company’s common stock trades on the NYSE American under the ticker symbol “ANVS”. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 26, 2021, the Company closed an underwritten public offering of 1,000,000 shares of its common stock at an offering price of $50.00 per share, for gross proceeds of $50.0 million. The net proceeds of the offering were approximately $46.6 million, after deducting underwriting discounts and issuance costs paid or payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of the date these financial statements are issued, management believes that the current cash and cash equivalents are sufficient to fund operations and capital requirements for at least the next 12 <span style="white-space:pre-wrap;">months, including the remaining costs of its Phase 2a clinical trial in AD and PD (the “AD/PD Trial”) which finished treating patients in the third quarter of 2021 and a potential Phase 3 trial in AD, PD, or DS-AD. In order to fund additional planned Phase 3 trials, however, the Company will need to raise additional capital. There is no assurance that such financing will be available when needed or on acceptable terms.</span></p> 2300000 6.00 13800000 12000000.0 100000 7.50 1.25 4117089 118470 1000000 50.00 50000000.0 46600000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(2) Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Basis of Presentation of Interim Unaudited Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">position of Annovis at September 30, 2021, and its results of operations and its cash flows for the three and nine months ended September 30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions include share-based compensation expense, the valuation of the derivative liability and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c) Basic and Diluted Net Income (Loss) per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes, warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d) Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)  Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Issuance costs incurred in connection with the Company’s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f) Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g) Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(h) Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(i) Share-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Determining the appropriate fair value of share-based awards requires the use of subjective assumptions including, in the case of stock options, the expected life of the option and expected share price volatility. The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(j) Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2021 and December 31, 2020, the Company has recorded a full valuation allowance against its deferred tax assets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at September 30, 2021 or December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(k) Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 1pt 0pt;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on the Company’s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 1pt 0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Basis of Presentation of Interim Unaudited Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">position of Annovis at September 30, 2021, and its results of operations and its cash flows for the three and nine months ended September 30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions include share-based compensation expense, the valuation of the derivative liability and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c) Basic and Diluted Net Income (Loss) per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes, warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d) Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)  Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Issuance costs incurred in connection with the Company’s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f) Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g) Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(h) Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(i) Share-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Determining the appropriate fair value of share-based awards requires the use of subjective assumptions including, in the case of stock options, the expected life of the option and expected share price volatility. The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(j) Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2021 and December 31, 2020, the Company has recorded a full valuation allowance against its deferred tax assets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at September 30, 2021 or December 31, 2020.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(k) Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 1pt 0pt;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on the Company’s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(3) Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,455,334</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,455,334</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,074,658</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,074,658</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,455,334</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,455,334</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,074,658</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,074,658</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 47455334 47455334 8074658 8074658 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(4) Grant Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of long-term chronic toxicology studies of ANVS401 in rats and dogs. The Company began the long-term chronic toxicology studies in November <span style="white-space:pre-wrap;">2019. The Company recognized grant income of $0 and $586,903 for the three months ended September 30, 2021 and 2020, respectively, and $36,754 and $952,602 for the nine months ended September 30, 2021 and 2020, respectively, in connection with the NIH grant. The Company received payments under the grant of $36,754 and $1,262,725 during the nine months ended September 30, 2021 and 2020, respectively. The Company </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">recorded a grant receivable of $0 as of September 30, 2021 and December 31, 2020, and had no unreimbursed, eligible costs incurred under the grant. As of September 30, 2021, there were no remaining funds available under the grant.</span></p> 1900000 0 586903 36754 952602 36754 1262725 0 0 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(5) Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 121,501</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,542</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,865</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,444</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 195,156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 121,501</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,542</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,865</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,444</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 195,156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 121501 26542 63790 11690 9865 6444 195156 44676 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(6) Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll and related benefits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 243,684</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,493</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional and clinical fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 548,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 216,198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued license payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,333</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,833</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 830,859</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236,524</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">See Note 8 for further detail on the accrued license payments.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll and related benefits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 243,684</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,493</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional and clinical fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 548,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 216,198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued license payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,333</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,833</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 830,859</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236,524</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 243684 16493 548842 216198 38333 3833 830859 236524 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(7) Convertible Promissory Notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2019, the Company issued convertible promissory notes (the “Notes”) to various investors in the aggregate principal amount of $530,000 with a stated interest rate of 8% compounded annually. On issuance, the Company recognized a discount associated with the Notes related to the fair value of an embedded derivative liability reflecting the share-settlement feature providing for the conversion of the Notes at a 20%<span style="white-space:pre-wrap;"> discount to the price of the shares issued in a qualified financing. The Company estimated the fair value of the derivative liability using a probability-weighted approach at issuance, as of the end of each reporting period and immediately prior to the closing of the IPO. The change in the fair value of the derivative liability was reflected in the statements of operations. The Company amortized deferred financing fees and debt discount over the term of the Notes as additional interest expense using the effective interest method. The effective interest rate on the Notes was </span>9.8%. The Company made no cash payments for interest on the Notes. On January 31, 2020, the Company closed its IPO and in accordance with the terms of the Notes, the outstanding Notes plus accrued interest converted into 118,470 shares of Company common stock.</p> 530000 0.08 0.20 0.098 0 118470 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(8) Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its office facilities under a month-to-month operating lease. Total rental expense was $13,410 and $10,394 for the three months ended September 30, 2021 and 2020, respectively and $36,600 and $31,209 for the nine months ended September 30, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company previously licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics from a subsidiary of Horizon Therapeutics, PLC (the “Licensor”). Under the license agreement, the Company pays a minimum annual commitment of $46,000 and is required to make milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Company has paid to the Licensor all annual fees through November 2020. At September 30, 2021 and December 31, 2020, the Company had accrued $38,333 and $3,833, respectively, in license payments under the term of this license, included in accrued liabilities. No milestones have been achieved as of September 30, 2021. The Licensor also granted the Company a buy-out option which may be exercised at any time during the term of the agreement at increasing amounts based on the achievement of certain milestones. The Company has the right to terminate the agreement at any time by giving <span style="white-space:pre-wrap;">90</span><span style="white-space:pre-wrap;"> days advance notice subject to the payment of any amounts due under the agreement at that time. Expenses related to the license agreement are recognized in general and administrative expense in the statements of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> In July 2021, the Company gave notice to the Licensor of its termination of the license agreement. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c) Employment Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The maximum aggregate severance payments under the Company’s employment agreements with its executive officers are approximately $930,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d) Litigation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the three months ended September 30, 2021, two<span style="white-space:pre-wrap;"> securities class action complaints were filed against the Company and its executive officers following disclosure of interim results from the AD/PD Trial. </span><span style="-sec-ix-hidden:Hidden_3kCDijDeS0mwhgqiBswY6A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Both</span></span> complaints were subsequently voluntarily dismissed without prejudice by the plaintiffs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e) Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The extent to which the COVID-19 pandemic could have a material impact on the Company’s current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. Management continues to evaluate the potential impact. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> 13410 10394 36600 31209 46000 38333 3833 0 P90D 930000 2 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(9) Redeemable Convertible Preferred Stock and Stockholders’ Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the closing of the Company’s IPO on January 31, 2020, the then-outstanding 5,133,159 shares of Series A and 630,722 shares of Series A-1 redeemable convertible preferred stock converted into an aggregate of 4,117,089 shares of Company common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020 to authorize the issuance of two classes of stock to be designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 37,000,000, each with a <span style="-sec-ix-hidden:Hidden_XDqzF21UoUymMgVM0-bGUg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">par value</span></span><span style="white-space:pre-wrap;"> of $0.0001 per share. Of these shares, 35,000,000 shall be common stock and 2,000,000 shall be preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">1.           Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">2.           Liquidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">3.           Voting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c) Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of September 30, 2021 or December 31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d) Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which was 125% of the initial public offering price. The warrants have a <span style="white-space:pre-wrap;">five-year</span><span style="white-space:pre-wrap;"> term and are exercisable commencing January 29, 2021. During the nine months ended September 30, 2021, 97,600</span><span style="white-space:pre-wrap;"> of the warrants were tendered to the Company by the holders pursuant to cashless exercises. As of September 30, 2021 and December 31, 2020, 2,400 and 100,000</span><span style="white-space:pre-wrap;"> of the warrants were outstanding, respectively. The Company accounts for the warrants as a component of stockholders’ equity.</span></p> 5133159 630722 4117089 2 37000000 0.0001 35000000 2000000 1 0 0 100000 7.50 1.25 P5Y 97600 2400 100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(10) Share-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective upon the closing of the Company’s IPO on January 31, 2020, the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective, succeeding the Company’s previous plan (see Note 1). As of the effective date of the 2019 Plan, the previous plan had 352,282 options outstanding 2019 Plan and no new awards may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 shares to 2,000,000<span style="white-space:pre-wrap;">. As of September 30, 2021, 1,084,464 shares were available for future grants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the nine months ended September 30, 2021, the Company granted options to purchase 84,200 shares of common stock at an exercise price of $102.85 per share to employees, members of its board of directors and consultants. Under the grant agreements, all of the options vest in substantially equal quarterly installments over <span style="white-space:pre-wrap;">two years</span><span style="white-space:pre-wrap;"> and have a </span><span style="white-space:pre-wrap;">10</span><span style="white-space:pre-wrap;">-year term. The options granted during the nine months ended September 30, 2021 were valued using the Black Scholes option pricing model using the following assumptions: (i) expected term of </span><span style="white-space:pre-wrap;">5.6</span><span style="white-space:pre-wrap;"> years; (ii) risk free interest rate of 0.87%; (iii) expected volatility of 104.0%; and (iv) dividend yield of 0.0</span><span style="white-space:pre-wrap;">%. The weighted-average grant date fair value of options issued by the Company during the nine months ended September 30, 2021 was $80.76 per share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;"> Share-based compensation expense, including the fair value of stock awards to consultants and advisors, for the three months ended September 30, 2021 and 2020 was $785,942 and $629,017, respectively, and for the nine months ended September 30, 2021 and 2020 was $817,911 and $1,740,289</span><span style="white-space:pre-wrap;">, respectively. As of September 30, 2021, there were </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">1,035,853 options outstanding, of which 951,653</span><span style="white-space:pre-wrap;"> were vested and exercisable. As of December 31, 2020, there were 1,111,466 options outstanding, of which 1,061,466 were vested and exercisable.</span></p> 352282 1000000 2000000 1084464 84200 102.85 P2Y P10Y P5Y7M6D 0.0087 1.040 0.000 80.76 785942 629017 817911 1740289 1035853 951653 1111466 1061466 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(11) Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of basic and diluted net loss per share:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,848,216)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,006,354)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,572,491)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,757,434)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,099,103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,871,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,466,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,113,400</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.61)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company reported a net loss for the three and nine months ended September 30, 2021 and 2020, therefore, the basic and diluted net loss per share are the same in the respective period because the inclusion of potential common shares would have an anti-dilutive effect. Potential shares of common stock that are excluded from the computation of diluted weighted-average shares outstanding are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:76.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,035,853</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,113,847</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, common shares issuable upon the conversion of the Notes were excluded for all periods in which the Notes were outstanding.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,848,216)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,006,354)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,572,491)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,757,434)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,099,103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,871,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,466,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,113,400</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.61)</p></td></tr></table> -2848216 -1006354 -8572491 -3757434 8099103 6871554 7466443 6113400 -0.35 -0.15 -1.15 -0.61 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:76.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,035,853</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,113,847</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100,000</p></td></tr></table> 1035853 1113847 2400 100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(12) Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s income tax benefit (expense) was $0 for the three and nine months ended September 30, 2021 and 2020. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss (“NOL”) that would have been recognized in the three and nine months ended September 30, 2021 and 2020 was offset by changes in the valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of September 30, 2021, and December 31, 2020, the Company had not recorded any liability for uncertain tax positions, accrued interest or penalties thereon, and no amounts have been recognized in the Company’s statements of operations.</p> 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(13) Related-Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As discussed in Note 7, in March 2019 the Company issued Notes in the aggregate principal amount of $530,000. Three of the Company’s directors purchased an aggregate of $305,000 of the Notes. On January 31, 2020, the Company closed its IPO, and the outstanding Notes plus accrued interest held by directors converted into 71,429 shares of Company common stock.</p> 530000 3 305000 71429 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p> XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2021
Nov. 01, 2021
Document and Entity Information    
Entity Registrant Name Annovis Bio, Inc.  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2021  
Document Transition Report false  
Entity File Number 001-39202  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 26-2540421  
Entity Address, Address Line One 1055 Westlakes Drive, Suite 300  
Entity Address, City or Town Berwyn  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19312  
City Area Code 610  
Local Phone Number 727-3913  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol ANVS  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   8,100,570
Entity Central Index Key 0001477845  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheets - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 47,455,334 $ 8,074,658
Prepaid expenses and other current assets 195,156 44,676
Total current assets 47,650,490 8,119,334
Total assets 47,650,490 8,119,334
Current liabilities:    
Accounts payable 289,742 341,856
Accrued expenses 830,859 236,524
Total current liabilities 1,120,601 578,380
Total liabilities 1,120,601 578,380
Commitments and contingencies (Note 8)
Stockholders' equity:    
Preferred stock - $0.0001 par value, 2,000,000 shares authorized, and 0 shares issued and outstanding
Common stock - $0.0001 par value, 35,000,000 shares authorized, and 6,947,120 and 6,891,608 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively 810 689
Additional paid-in capital 69,340,645 21,779,340
Accumulated deficit (22,811,566) (14,239,075)
Total stockholders' equity 46,529,889 7,540,954
Total liabilities and stockholders' equity $ 47,650,490 $ 8,119,334
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Balance Sheets    
Preferred stock, par value (dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 2,000,000 2,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 35,000,000 35,000,000
Common stock, shares issued 8,100,570 6,891,608
Common stock, shares outstanding 8,100,570 6,891,608
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating expenses:        
Research and development $ 1,380,801 $ 718,898 $ 5,594,886 $ 1,641,822
General and administrative 1,472,969 884,859 3,022,244 3,088,726
Total operating expenses 2,853,770 1,603,757 8,617,130 4,730,548
Operating loss (2,853,770) (1,603,757) (8,617,130) (4,730,548)
Other income (expense):        
Change in fair value of derivative liability       (26,500)
Interest income, net 5,554 10,500 7,885 47,012
Grant income   586,903 36,754 952,602
Total other income (expense) 5,554 597,403 44,639 973,114
Loss before income taxes (2,848,216) (1,006,354) (8,572,491) (3,757,434)
Income tax expense (benefit) 0   0  
Net loss $ (2,848,216) $ (1,006,354) $ (8,572,491) $ (3,757,434)
Basic loss per common share $ (0.35) $ (0.15) $ (1.15) $ (0.61)
Diluted loss per common share $ (0.35) $ (0.15) $ (1.15) $ (0.61)
Weighted average number of common shares outstanding, basic 8,099,103 6,871,554 7,466,443 6,113,400
Weighted average number of common shares outstanding, diluted 8,099,103 6,871,554 7,466,443 6,113,400
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Statements of Changes in Redeemable Convertible Preferred Stock
3 Months Ended
Mar. 31, 2020
USD ($)
shares
Series A Redeemable convertible preferred stock  
Changes in Redeemable Convertible Preferred Stock  
Balance | $ $ 6,509,303
Balance, shares | shares 5,133,159
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering | $ $ (6,509,303)
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares | shares (5,133,159)
Balance | $ $ 0
Balance, shares | shares 0
Series A-1 Redeemable convertible preferred stock  
Changes in Redeemable Convertible Preferred Stock  
Balance | $ $ 567,649
Balance, shares | shares 630,722
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering | $ $ (567,649)
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares | shares (630,722)
Balance | $ $ 0
Balance, shares | shares 0
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2019 $ 28 $ 200,600 $ (8,777,028) $ (8,576,400)
Balance, shares at Dec. 31, 2019 282,614      
Changes in Stockholders' Equity        
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering $ 412 7,076,540   7,076,952
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares 4,117,089      
Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering $ 12 672,512   672,524
Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering, shares 118,470      
Issuance of common stock in initial public offering, net of issuance costs $ 230 11,955,565   11,955,795
Issuance of common stock in initial public offering, net of issuance costs (in shares) 2,300,000      
Exercise of stock options $ 3 4,603   4,606
Exercise of stock options, shares 27,286      
Net loss     (441,590) (441,590)
Balance at Mar. 31, 2020 $ 685 19,909,820 (9,218,618) 10,691,887
Balance, shares at Mar. 31, 2020 6,845,459      
Balance at Dec. 31, 2019 $ 28 200,600 (8,777,028) (8,576,400)
Balance, shares at Dec. 31, 2019 282,614      
Changes in Stockholders' Equity        
Net loss       (3,757,434)
Balance at Sep. 30, 2020 $ 687 21,654,718 (12,534,462) 9,120,943
Balance, shares at Sep. 30, 2020 6,871,608      
Balance at Mar. 31, 2020 $ 685 19,909,820 (9,218,618) 10,691,887
Balance, shares at Mar. 31, 2020 6,845,459      
Changes in Stockholders' Equity        
Exercise of stock options $ 2 4,609   4,611
Exercise of stock options, shares 21,149      
Share based compensation expense   1,111,272   1,111,272
Net loss     (2,309,490) (2,309,490)
Balance at Jun. 30, 2020 $ 687 21,025,701 (11,528,108) 9,498,280
Balance, shares at Jun. 30, 2020 6,866,608      
Changes in Stockholders' Equity        
Issuance of common stock to consultants and advisors   21,950   21,950
Issuance of common stock to consultants and advisors, shares 5,000      
Share based compensation expense   607,067   607,067
Net loss     (1,006,354) (1,006,354)
Balance at Sep. 30, 2020 $ 687 21,654,718 (12,534,462) 9,120,943
Balance, shares at Sep. 30, 2020 6,871,608      
Balance at Dec. 31, 2020 $ 689 21,779,340 (14,239,075) 7,540,954
Balance, shares at Dec. 31, 2020 6,891,608      
Changes in Stockholders' Equity        
Exercise of stock options $ 1 3,016   3,017
Exercise of stock options, shares 3,868      
Exercise of warrants $ 5 (5)    
Exercise of warrants, shares 51,644      
Share based compensation expense   23,977   23,977
Net loss     (3,199,673) (3,199,673)
Balance at Mar. 31, 2021 $ 695 21,806,328 (17,438,748) 4,368,275
Balance, shares at Mar. 31, 2021 6,947,120      
Balance at Dec. 31, 2020 $ 689 21,779,340 (14,239,075) 7,540,954
Balance, shares at Dec. 31, 2020 6,891,608      
Changes in Stockholders' Equity        
Net loss       (8,572,491)
Balance at Sep. 30, 2021 $ 810 69,340,645 (22,811,566) 46,529,889
Balance, shares at Sep. 30, 2021 8,100,570      
Balance at Mar. 31, 2021 $ 695 21,806,328 (17,438,748) 4,368,275
Balance, shares at Mar. 31, 2021 6,947,120      
Changes in Stockholders' Equity        
Issuance of common stock in initial public offering, net of issuance costs $ 100 46,668,313   46,668,413
Issuance of common stock in initial public offering, net of issuance costs (in shares) 1,000,000      
Exercise of stock options $ 14 92,071   92,085
Exercise of stock options, shares 141,532      
Exercise of warrants, shares 2,280      
Share based compensation expense   7,992   7,992
Net loss     (2,524,602) (2,524,602)
Balance at Jun. 30, 2021 $ 809 68,574,704 (19,963,350) 48,612,163
Balance, shares at Jun. 30, 2021 8,090,932      
Changes in Stockholders' Equity        
Issuance costs   (20,000)   (20,000)
Exercise of stock options $ 1 (1)    
Exercise of stock options, shares 9,638      
Share based compensation expense   785,942   785,942
Net loss     (2,848,216) (2,848,216)
Balance at Sep. 30, 2021 $ 810 $ 69,340,645 $ (22,811,566) $ 46,529,889
Balance, shares at Sep. 30, 2021 8,100,570      
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Statements of Cash Flows - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net loss $ (8,572,491) $ (3,757,434)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of deferred financing fees   129
Amortization of debt discount   396
Share-based compensation expense, including stock issued to consultants and advisors 817,911 1,740,289
Change in fair value of derivative liability   26,500
Changes in operating assets and liabilities:    
Grant receivable   310,123
Prepaid expenses and other current assets (150,480) (125,863)
Accounts payable (52,114) (897,739)
Accrued expenses 594,335 (501,275)
Net cash used in operating activities (7,362,839) (3,204,874)
Cash flows from financing activities:    
Proceeds from issuance of common stock, net of issuance costs 46,648,413 12,034,406
Proceeds from exercise of stock options 95,102 9,217
Net cash provided by financing activities 46,743,515 12,043,623
Net increase in cash and cash equivalents 39,380,676 8,838,749
Cash and cash equivalents, beginning of year 8,074,658 1,858
Cash and cash equivalents, end of year $ 47,455,334 8,840,607
Supplemental disclosure of non-cash financing activities:    
Conversion of redeemable convertible preferred stock to common stock   7,076,952
Conversion of convertible promissory notes, including embedded derivative, to common stock   $ 672,524
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Nature of Business and Liquidity
9 Months Ended
Sep. 30, 2021
Nature of Business and Liquidity  
Nature of Business and Liquidity

(1) Nature of Business and Liquidity

Annovis Bio, Inc. (the “Company” or “Annovis”) was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”) and Down syndrome patients with AD (“DS-AD”). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company’s lead compound, ANVS401, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.

Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.

The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of equity securities.

The Company closed its initial public offering (the “IPO”) on January 31, 2020, pursuant to which it sold a total of 2,300,000 shares of common stock at an initial offering price of $6.00 per share for total gross proceeds of approximately $13.8 million. The net proceeds of the IPO were approximately $12.0 million after deducting underwriting discounts and issuance costs paid by the Company. In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. Upon the closing of the IPO, outstanding redeemable convertible preferred stock and convertible promissory notes converted into shares of Company common stock totaling 4,117,089 and 118,470, respectively. The Company’s common stock trades on the NYSE American under the ticker symbol “ANVS”.

On May 26, 2021, the Company closed an underwritten public offering of 1,000,000 shares of its common stock at an offering price of $50.00 per share, for gross proceeds of $50.0 million. The net proceeds of the offering were approximately $46.6 million, after deducting underwriting discounts and issuance costs paid or payable by the Company.

As of the date these financial statements are issued, management believes that the current cash and cash equivalents are sufficient to fund operations and capital requirements for at least the next 12 months, including the remaining costs of its Phase 2a clinical trial in AD and PD (the “AD/PD Trial”) which finished treating patients in the third quarter of 2021 and a potential Phase 3 trial in AD, PD, or DS-AD. In order to fund additional planned Phase 3 trials, however, the Company will need to raise additional capital. There is no assurance that such financing will be available when needed or on acceptable terms.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2021
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation of Interim Unaudited Financial Statements

The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial

position of Annovis at September 30, 2021, and its results of operations and its cash flows for the three and nine months ended September 30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.

Significant items subject to such estimates and assumptions include share-based compensation expense, the valuation of the derivative liability and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.

(c) Basic and Diluted Net Income (Loss) per Share

Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes, warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.

(d) Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.

(e)  Issuance Costs Associated with Equity Issuances

Issuance costs incurred in connection with the Company’s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed.

(f) Fair Value of Financial Instruments

The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature.

(g) Research and Development

Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.

(h) Grant Income

Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.

(i) Share-Based Compensation

Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.

Determining the appropriate fair value of share-based awards requires the use of subjective assumptions including, in the case of stock options, the expected life of the option and expected share price volatility. The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.

The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

(j) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2021 and December 31, 2020, the Company has recorded a full valuation allowance against its deferred tax assets.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at September 30, 2021 or December 31, 2020.

(k) Recent Accounting Pronouncements

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on the Company’s financial statements.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements
9 Months Ended
Sep. 30, 2021
Fair Value Measurements  
Fair Value Measurements

(3) Fair Value Measurements

The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:

    

    

Fair Value Measurement at

September 30, 2021

Carrying Value

Level 1

Level 2

Level 3

Cash and cash equivalents

$

47,455,334

$

47,455,334

$

$

    

    

Fair Value Measurement at

December 31, 2020

Carrying Value

Level 1

Level 2

Level 3

Cash and cash equivalents

$

8,074,658

$

8,074,658

$

$

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Grant Receivable
9 Months Ended
Sep. 30, 2021
Grant Receivable  
Grant Receivable

(4) Grant Receivable

In September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of long-term chronic toxicology studies of ANVS401 in rats and dogs. The Company began the long-term chronic toxicology studies in November 2019. The Company recognized grant income of $0 and $586,903 for the three months ended September 30, 2021 and 2020, respectively, and $36,754 and $952,602 for the nine months ended September 30, 2021 and 2020, respectively, in connection with the NIH grant. The Company received payments under the grant of $36,754 and $1,262,725 during the nine months ended September 30, 2021 and 2020, respectively. The Company

recorded a grant receivable of $0 as of September 30, 2021 and December 31, 2020, and had no unreimbursed, eligible costs incurred under the grant. As of September 30, 2021, there were no remaining funds available under the grant.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Prepaid Expenses and Other Current Assets
9 Months Ended
Sep. 30, 2021
Prepaid Expenses and Other Current Assets  
Prepaid Expenses and Other Current Assets

(5) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

    

September 30, 

December 31, 

2021

2020

Prepaid insurance

$

121,501

$

26,542

Prepaid expenses

 

63,790

 

11,690

Security deposit

 

9,865

 

6,444

$

195,156

$

44,676

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses
9 Months Ended
Sep. 30, 2021
Accrued Expenses  
Accrued Expenses

(6) Accrued Expenses

Accrued expenses consisted of the following:

    

September 30, 

December 31, 

2021

2020

Payroll and related benefits

$

243,684

$

16,493

Accrued professional and clinical fees

 

548,842

 

216,198

Accrued license payments

 

38,333

 

3,833

$

830,859

$

236,524

See Note 8 for further detail on the accrued license payments.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Convertible Promissory Notes
9 Months Ended
Sep. 30, 2021
Convertible Promissory Notes.  
Convertible Promissory Notes

(7) Convertible Promissory Notes

In March 2019, the Company issued convertible promissory notes (the “Notes”) to various investors in the aggregate principal amount of $530,000 with a stated interest rate of 8% compounded annually. On issuance, the Company recognized a discount associated with the Notes related to the fair value of an embedded derivative liability reflecting the share-settlement feature providing for the conversion of the Notes at a 20% discount to the price of the shares issued in a qualified financing. The Company estimated the fair value of the derivative liability using a probability-weighted approach at issuance, as of the end of each reporting period and immediately prior to the closing of the IPO. The change in the fair value of the derivative liability was reflected in the statements of operations. The Company amortized deferred financing fees and debt discount over the term of the Notes as additional interest expense using the effective interest method. The effective interest rate on the Notes was 9.8%. The Company made no cash payments for interest on the Notes. On January 31, 2020, the Company closed its IPO and in accordance with the terms of the Notes, the outstanding Notes plus accrued interest converted into 118,470 shares of Company common stock.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2021
Commitments and Contingencies  
Commitments and Contingencies

(8) Commitments and Contingencies

(a) Leases

The Company leases its office facilities under a month-to-month operating lease. Total rental expense was $13,410 and $10,394 for the three months ended September 30, 2021 and 2020, respectively and $36,600 and $31,209 for the nine months ended September 30, 2021 and 2020, respectively.

(b) License Agreement

The Company previously licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics from a subsidiary of Horizon Therapeutics, PLC (the “Licensor”). Under the license agreement, the Company pays a minimum annual commitment of $46,000 and is required to make milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Company has paid to the Licensor all annual fees through November 2020. At September 30, 2021 and December 31, 2020, the Company had accrued $38,333 and $3,833, respectively, in license payments under the term of this license, included in accrued liabilities. No milestones have been achieved as of September 30, 2021. The Licensor also granted the Company a buy-out option which may be exercised at any time during the term of the agreement at increasing amounts based on the achievement of certain milestones. The Company has the right to terminate the agreement at any time by giving 90 days advance notice subject to the payment of any amounts due under the agreement at that time. Expenses related to the license agreement are recognized in general and administrative expense in the statements of operations.

In July 2021, the Company gave notice to the Licensor of its termination of the license agreement.

(c) Employment Agreements

The maximum aggregate severance payments under the Company’s employment agreements with its executive officers are approximately $930,000.

(d) Litigation

The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.

During the three months ended September 30, 2021, two securities class action complaints were filed against the Company and its executive officers following disclosure of interim results from the AD/PD Trial. Both complaints were subsequently voluntarily dismissed without prejudice by the plaintiffs.

(e) Risks and Uncertainties

The extent to which the COVID-19 pandemic could have a material impact on the Company’s current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. Management continues to evaluate the potential impact. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Redeemable Convertible Preferred Stock and Stockholders' Equity
9 Months Ended
Sep. 30, 2021
Redeemable Convertible Preferred Stock and Stockholders' Equity  
Redeemable Convertible Preferred Stock and Stockholders' Equity

(9) Redeemable Convertible Preferred Stock and Stockholders’ Equity

(a) Overview

In connection with the closing of the Company’s IPO on January 31, 2020, the then-outstanding 5,133,159 shares of Series A and 630,722 shares of Series A-1 redeemable convertible preferred stock converted into an aggregate of 4,117,089 shares of Company common stock.

The Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020 to authorize the issuance of two classes of stock to be designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 37,000,000, each with a par value of $0.0001 per share. Of these shares, 35,000,000 shall be common stock and 2,000,000 shall be preferred stock.

(b) Common Stock

1.           Dividends

Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.

2.           Liquidation

Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.

3.           Voting

The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.

(c) Preferred Stock

Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of September 30, 2021 or December 31, 2020.

(d) Warrants

In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which was 125% of the initial public offering price. The warrants have a five-year term and are exercisable commencing January 29, 2021. During the nine months ended September 30, 2021, 97,600 of the warrants were tendered to the Company by the holders pursuant to cashless exercises. As of September 30, 2021 and December 31, 2020, 2,400 and 100,000 of the warrants were outstanding, respectively. The Company accounts for the warrants as a component of stockholders’ equity.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation
9 Months Ended
Sep. 30, 2021
Share-Based Compensation  
Share-Based Compensation

(10) Share-Based Compensation

Effective upon the closing of the Company’s IPO on January 31, 2020, the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective, succeeding the Company’s previous plan (see Note 1). As of the effective date of the 2019 Plan, the previous plan had 352,282 options outstanding 2019 Plan and no new awards may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 shares to 2,000,000. As of September 30, 2021, 1,084,464 shares were available for future grants.

During the nine months ended September 30, 2021, the Company granted options to purchase 84,200 shares of common stock at an exercise price of $102.85 per share to employees, members of its board of directors and consultants. Under the grant agreements, all of the options vest in substantially equal quarterly installments over two years and have a 10-year term. The options granted during the nine months ended September 30, 2021 were valued using the Black Scholes option pricing model using the following assumptions: (i) expected term of 5.6 years; (ii) risk free interest rate of 0.87%; (iii) expected volatility of 104.0%; and (iv) dividend yield of 0.0%. The weighted-average grant date fair value of options issued by the Company during the nine months ended September 30, 2021 was $80.76 per share.

Share-based compensation expense, including the fair value of stock awards to consultants and advisors, for the three months ended September 30, 2021 and 2020 was $785,942 and $629,017, respectively, and for the nine months ended September 30, 2021 and 2020 was $817,911 and $1,740,289, respectively. As of September 30, 2021, there were

1,035,853 options outstanding, of which 951,653 were vested and exercisable. As of December 31, 2020, there were 1,111,466 options outstanding, of which 1,061,466 were vested and exercisable.

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss Per Share
9 Months Ended
Sep. 30, 2021
Net Loss Per Share  
Net Loss Per Share

(11) Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2021

    

2020

    

2021

    

2020

Numerator:

 

  

 

  

  

 

  

Net loss

$

(2,848,216)

$

(1,006,354)

$

(8,572,491)

$

(3,757,434)

Denominator:

 

  

 

  

 

  

 

  

Weighted-average common shares outstanding, basic and diluted

 

8,099,103

 

6,871,554

 

7,466,443

 

6,113,400

Net loss per share, basic and diluted

$

(0.35)

$

(0.15)

$

(1.15)

$

(0.61)

The Company reported a net loss for the three and nine months ended September 30, 2021 and 2020, therefore, the basic and diluted net loss per share are the same in the respective period because the inclusion of potential common shares would have an anti-dilutive effect. Potential shares of common stock that are excluded from the computation of diluted weighted-average shares outstanding are as follows:

September 30, 

    

2021

    

2020

Stock options

1,035,853

1,113,847

Warrants

 

2,400

 

100,000

In addition, common shares issuable upon the conversion of the Notes were excluded for all periods in which the Notes were outstanding.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
9 Months Ended
Sep. 30, 2021
Income Taxes  
Income Taxes

(12) Income Taxes

The Company’s income tax benefit (expense) was $0 for the three and nine months ended September 30, 2021 and 2020. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss (“NOL”) that would have been recognized in the three and nine months ended September 30, 2021 and 2020 was offset by changes in the valuation allowance.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.

Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.

As of September 30, 2021, and December 31, 2020, the Company had not recorded any liability for uncertain tax positions, accrued interest or penalties thereon, and no amounts have been recognized in the Company’s statements of operations.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Related-Party Transactions
9 Months Ended
Sep. 30, 2021
Related-Party Transactions  
Related-Party Transactions

(13) Related-Party Transactions

As discussed in Note 7, in March 2019 the Company issued Notes in the aggregate principal amount of $530,000. Three of the Company’s directors purchased an aggregate of $305,000 of the Notes. On January 31, 2020, the Company closed its IPO, and the outstanding Notes plus accrued interest held by directors converted into 71,429 shares of Company common stock.

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events
9 Months Ended
Sep. 30, 2021
Subsequent Events  
Subsequent Events

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2021
Summary of Significant Accounting Policies  
Basis of Presentation of Interim Unaudited Financial Statements

(a) Basis of Presentation of Interim Unaudited Financial Statements

The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial

position of Annovis at September 30, 2021, and its results of operations and its cash flows for the three and nine months ended September 30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.

Use of Estimates

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.

Significant items subject to such estimates and assumptions include share-based compensation expense, the valuation of the derivative liability and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.

Basic and Diluted Net Income (Loss) per Share

(c) Basic and Diluted Net Income (Loss) per Share

Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes, warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.

Cash and Cash Equivalents

(d) Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.

Issuance Costs Associated with Equity Issuances

(e)  Issuance Costs Associated with Equity Issuances

Issuance costs incurred in connection with the Company’s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed.

Fair Value of Financial Instruments

(f) Fair Value of Financial Instruments

The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature.

Research and Development

(g) Research and Development

Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.

Grant Income

(h) Grant Income

Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.

Share-Based Compensation

(i) Share-Based Compensation

Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.

Determining the appropriate fair value of share-based awards requires the use of subjective assumptions including, in the case of stock options, the expected life of the option and expected share price volatility. The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.

The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

Income Taxes

(j) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2021 and December 31, 2020, the Company has recorded a full valuation allowance against its deferred tax assets.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at September 30, 2021 or December 31, 2020.

Recent Accounting Pronouncements

(k) Recent Accounting Pronouncements

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on the Company’s financial statements.

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2021
Fair Value Measurements  
Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:

    

    

Fair Value Measurement at

September 30, 2021

Carrying Value

Level 1

Level 2

Level 3

Cash and cash equivalents

$

47,455,334

$

47,455,334

$

$

    

    

Fair Value Measurement at

December 31, 2020

Carrying Value

Level 1

Level 2

Level 3

Cash and cash equivalents

$

8,074,658

$

8,074,658

$

$

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Prepaid Expenses and Other Current Assets (Tables)
9 Months Ended
Sep. 30, 2021
Prepaid Expenses and Other Current Assets  
Schedule of prepaid expenses and other current assets

    

September 30, 

December 31, 

2021

2020

Prepaid insurance

$

121,501

$

26,542

Prepaid expenses

 

63,790

 

11,690

Security deposit

 

9,865

 

6,444

$

195,156

$

44,676

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses (Tables)
9 Months Ended
Sep. 30, 2021
Accrued Expenses  
Schedule of accrued expenses

    

September 30, 

December 31, 

2021

2020

Payroll and related benefits

$

243,684

$

16,493

Accrued professional and clinical fees

 

548,842

 

216,198

Accrued license payments

 

38,333

 

3,833

$

830,859

$

236,524

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss Per Share (Tables)
9 Months Ended
Sep. 30, 2021
Net Loss Per Share  
Schedule of basic and diluted net loss per share

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2021

    

2020

    

2021

    

2020

Numerator:

 

  

 

  

  

 

  

Net loss

$

(2,848,216)

$

(1,006,354)

$

(8,572,491)

$

(3,757,434)

Denominator:

 

  

 

  

 

  

 

  

Weighted-average common shares outstanding, basic and diluted

 

8,099,103

 

6,871,554

 

7,466,443

 

6,113,400

Net loss per share, basic and diluted

$

(0.35)

$

(0.15)

$

(1.15)

$

(0.61)

Schedule of shares excluded from the computation of diluted weighted-average shares outstanding

September 30, 

    

2021

    

2020

Stock options

1,035,853

1,113,847

Warrants

 

2,400

 

100,000

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Nature of Business and Liquidity (Details) - USD ($)
3 Months Ended 9 Months Ended
May 26, 2021
Jan. 31, 2020
Jun. 30, 2021
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Nature of Business and Liquidity              
Revenue         $ 0    
Accumulated deficit         (22,811,566)   $ (14,239,075)
Gross proceeds from issuance of common shares         $ 46,648,413 $ 12,034,406  
Underwriters warrants              
Nature of Business and Liquidity              
Number of warrants issued   100,000          
Exercise price   $ 7.50          
Percentage of exercise price to the share offering price   125.00%          
Common Stock              
Nature of Business and Liquidity              
Issuance of common stock     1,000,000 2,300,000      
Number of shares issued for the conversion of redeemable convertible preferred stock       4,117,089      
Number of common shares issued upon conversion of notes       118,470      
Common Stock | IPO and Over-Allotment Option              
Nature of Business and Liquidity              
Share price   $ 6.00          
Gross proceeds from issuance of common shares   $ 13,800,000          
Net proceeds from issuance of common shares   $ 12,000,000.0          
Common Stock | IPO              
Nature of Business and Liquidity              
Issuance of common stock   2,300,000          
Number of shares issued for the conversion of redeemable convertible preferred stock   4,117,089          
Number of common shares issued upon conversion of notes   118,470          
Common Stock | Secondary Public Offering              
Nature of Business and Liquidity              
Issuance of common stock 1,000,000            
Share price $ 50.00            
Gross proceeds from issuance of common shares $ 50,000,000.0            
Net proceeds from issuance of common shares $ 46,600,000            
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Details) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Fair Value Measurements    
Cash and cash equivalents, Carrying Value $ 47,455,334 $ 8,074,658
Recurring | Level 1    
Fair Value Measurements    
Cash and cash equivalents, Fair Value $ 47,455,334 $ 8,074,658
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Grant Receivable (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Sep. 30, 2019
Grant Receivable            
Grant income   $ 586,903 $ 36,754 $ 952,602    
Unreimbursed, eligible costs incurred under the grant     0   $ 0  
Remining funds available $ 0   0      
NIH            
Grant Receivable            
Notice of Award, grant amount           $ 1,900,000
Grant income 0 $ 586,903 36,754 952,602    
Proceeds from grants     36,754 $ 1,262,725    
Grant receivable $ 0   $ 0   $ 0  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Prepaid Expenses and Other Current Assets (Details) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Prepaid Expenses and Other Current Assets    
Prepaid insurance $ 121,501 $ 26,542
Prepaid expenses 63,790 11,690
Security deposit 9,865 6,444
Total prepaid expenses and other current assets $ 195,156 $ 44,676
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses (Details) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Accrued Expenses    
Payroll and related benefits $ 243,684 $ 16,493
Accrued professional and clinical fees 548,842 216,198
Accrued license payments 38,333 3,833
Total accrued expenses $ 830,859 $ 236,524
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Convertible Promissory Notes (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Dec. 31, 2019
Common Stock        
Convertible Promissory Notes        
Number of common shares issued upon conversion of notes     118,470  
Common Stock | IPO        
Convertible Promissory Notes        
Number of common shares issued upon conversion of notes 118,470      
Convertible promissory notes        
Convertible Promissory Notes        
Aggregate principal amount   $ 530,000    
Stated interest rate   8.00%    
Effective interest rate   9.80%    
Cash payments for interest       $ 0
Percentage of discount to the initial offering price of shares issued in the IPO   20.00%    
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies - Leases (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Leases        
Rental expense $ 13,410 $ 10,394 $ 36,600 $ 31,209
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies - License Agreement (Details)
1 Months Ended 9 Months Ended
Nov. 30, 2008
USD ($)
Sep. 30, 2021
USD ($)
item
Dec. 31, 2020
USD ($)
License Agreements      
Accrued license payments   $ 38,333 $ 3,833
License Agreement | Horizon Therapeutics, PLC      
License Agreements      
Minimum annual commitment $ 46,000    
Amended License Agreement | Horizon Therapeutics, PLC      
License Agreements      
Accrued license payments   $ 38,333 $ 3,833
Number of milestones achieved | item   0  
Period for advance notice of termination   90 days  
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies - Employment Agreements and Litigation (Details)
3 Months Ended
Sep. 30, 2021
USD ($)
lawsuit
Litigation  
Number of new claims filed 2
Number of complaints dismissed during the period 2
Executive Officers  
Employment Agreements  
Maximum aggregate severance payments | $ $ 930,000
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)
3 Months Ended
Jan. 31, 2020
Vote
item
$ / shares
shares
Jun. 30, 2021
shares
Mar. 31, 2020
shares
Sep. 30, 2021
$ / shares
shares
Dec. 31, 2020
$ / shares
shares
Redeemable Convertible Preferred Stock and Stockholders' Equity          
Number of classes of stock designated | item 2        
Number of common and preferred shares authorized 37,000,000        
Common stock, par value (dollars per share) | $ / shares $ 0.0001     $ 0.0001 $ 0.0001
Preferred stock, par value (dollars per share) | $ / shares $ 0.0001     $ 0.0001 $ 0.0001
Number of common shares authorized 35,000,000     35,000,000 35,000,000
Number of preferred shares authorized 2,000,000     2,000,000 2,000,000
Number of vote for each share of common stock | Vote 1        
Preferred stock, shares issued       0 0
Preferred stock, shares outstanding       0 0
Series A Redeemable convertible preferred stock          
Redeemable Convertible Preferred Stock and Stockholders' Equity          
Conversion of redeemable convertible preferred stock to common stock, shares 5,133,159   5,133,159    
Series A-1 Redeemable convertible preferred stock          
Redeemable Convertible Preferred Stock and Stockholders' Equity          
Conversion of redeemable convertible preferred stock to common stock, shares 630,722   630,722    
Common Stock          
Redeemable Convertible Preferred Stock and Stockholders' Equity          
Issuance of common stock   1,000,000 2,300,000    
Number of shares issued for the conversion of redeemable convertible preferred stock     4,117,089    
Common Stock | IPO          
Redeemable Convertible Preferred Stock and Stockholders' Equity          
Issuance of common stock 2,300,000        
Number of shares issued for the conversion of redeemable convertible preferred stock 4,117,089        
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details) - Underwriters warrants - $ / shares
9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Jan. 31, 2020
Warrants      
Number of warrants issued     100,000
Exercise price     $ 7.50
Percentage of exercise price to the share offering price     125.00%
Warrant term     5 years
Number of warrants converted in a non-cash transaction 97,600    
Warrants outstanding 2,400 100,000  
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Jun. 01, 2021
May 31, 2021
Dec. 31, 2020
Jan. 31, 2020
Share-Based Compensation                
Options outstanding 1,035,853   1,035,853       1,111,466  
Shares available for future grants 1,084,464   1,084,464          
Options granted     84,200          
Exercise price     $ 102.85          
Share-based compensation expense     $ 817,911 $ 1,740,289        
Options, vested and exercisable 951,653   951,653       1,061,466  
Stock Options                
Share-Based Compensation                
Vesting period     2 years          
Term of award     10 years          
Expected term (in years)     5 years 7 months 6 days          
Risk-free interest rate     0.87%          
Expected volatility     104.00%          
Dividend yield (as a percent)     0.00%          
Weighted average grant date fair value     $ 80.76          
Share-based compensation expense $ 785,942 $ 629,017 $ 817,911 $ 1,740,289        
Previous Plans                
Share-Based Compensation                
Options outstanding               352,282
2019 Plan                
Share-Based Compensation                
Shares authorized         2,000,000 1,000,000    
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss Per Share - Basic and diluted net loss per share (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Numerator                
Net loss $ (2,848,216) $ (2,524,602) $ (3,199,673) $ (1,006,354) $ (2,309,490) $ (441,590) $ (8,572,491) $ (3,757,434)
Denominator                
Weighted-average common shares outstanding, basic 8,099,103     6,871,554     7,466,443 6,113,400
Weighted-average common shares outstanding, diluted 8,099,103     6,871,554     7,466,443 6,113,400
Net loss per share, basic $ (0.35)     $ (0.15)     $ (1.15) $ (0.61)
Net loss per share, diluted $ (0.35)     $ (0.15)     $ (1.15) $ (0.61)
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss Per Share - Potential shares excluded from calculation (Details) - shares
6 Months Ended 9 Months Ended
Jun. 30, 2020
Sep. 30, 2021
Stock Options    
Net Loss Per Share    
Antidilutive securities excluded from computation of earnings per share 1,113,847 1,035,853
Warrants    
Net Loss Per Share    
Antidilutive securities excluded from computation of earnings per share 100,000 2,400
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Income Taxes    
Income tax expense (benefit) $ 0.0 $ 0.0
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Related-Party Transactions (Details)
1 Months Ended 3 Months Ended
Jan. 31, 2020
shares
Mar. 31, 2019
USD ($)
item
Mar. 31, 2020
shares
Common Stock      
Related-Party Transactions      
Number of common shares issued upon conversion of notes | shares     118,470
Convertible promissory notes      
Related-Party Transactions      
Aggregate principal amount | $   $ 530,000  
Issuance of convertible promissory notes to related parties | Convertible promissory notes      
Related-Party Transactions      
Number of directors who purchased convertible promissory notes issued by the Company | item   3  
Directors | Issuance of convertible promissory notes to related parties | Convertible promissory notes      
Related-Party Transactions      
Aggregate principal amount | $   $ 305,000  
Directors | Conversion of promissory notes to common stock | Convertible promissory notes | Common Stock      
Related-Party Transactions      
Number of common shares issued upon conversion of notes | shares 71,429    
EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 55 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 109 250 1 false 25 0 false 7 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://annovisbio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Balance Sheets Sheet http://annovisbio.com/role/StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Balance Sheets (Parenthetical) Sheet http://annovisbio.com/role/StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Statements of Operations Sheet http://annovisbio.com/role/StatementStatementsOfOperations Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Statements of Changes in Redeemable Convertible Preferred Stock Sheet http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock Statements of Changes in Redeemable Convertible Preferred Stock Statements 5 false false R6.htm 00301 - Statement - Statements of Changes in Stockholders' Equity (Deficit) Sheet http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit Statements of Changes in Stockholders' Equity (Deficit) Statements 6 false false R7.htm 00400 - Statement - Statements of Cash Flows Sheet http://annovisbio.com/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - Nature of Business and Liquidity Sheet http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity Nature of Business and Liquidity Notes 8 false false R9.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 10301 - Disclosure - Fair Value Measurements Sheet http://annovisbio.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 10401 - Disclosure - Grant Receivable Sheet http://annovisbio.com/role/DisclosureGrantReceivable Grant Receivable Notes 11 false false R12.htm 10501 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 12 false false R13.htm 10601 - Disclosure - Accrued Expenses Sheet http://annovisbio.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 13 false false R14.htm 10701 - Disclosure - Convertible Promissory Notes Notes http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes Convertible Promissory Notes Notes 14 false false R15.htm 10801 - Disclosure - Commitments and Contingencies Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 10901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity Sheet http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity Redeemable Convertible Preferred Stock and Stockholders' Equity Notes 16 false false R17.htm 11001 - Disclosure - Share-Based Compensation Sheet http://annovisbio.com/role/DisclosureShareBasedCompensation Share-Based Compensation Notes 17 false false R18.htm 11101 - Disclosure - Net Loss Per Share Sheet http://annovisbio.com/role/DisclosureNetLossPerShare Net Loss Per Share Notes 18 false false R19.htm 11201 - Disclosure - Income Taxes Sheet http://annovisbio.com/role/DisclosureIncomeTaxes Income Taxes Notes 19 false false R20.htm 11301 - Disclosure - Related-Party Transactions Sheet http://annovisbio.com/role/DisclosureRelatedPartyTransactions Related-Party Transactions Notes 20 false false R21.htm 11401 - Disclosure - Subsequent Events Sheet http://annovisbio.com/role/DisclosureSubsequentEvents Subsequent Events Notes 21 false false R22.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 30303 - Disclosure - Fair Value Measurements (Tables) Sheet http://annovisbio.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://annovisbio.com/role/DisclosureFairValueMeasurements 23 false false R24.htm 30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 24 false false R25.htm 30603 - Disclosure - Accrued Expenses (Tables) Sheet http://annovisbio.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://annovisbio.com/role/DisclosureAccruedExpenses 25 false false R26.htm 31103 - Disclosure - Net Loss Per Share (Tables) Sheet http://annovisbio.com/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://annovisbio.com/role/DisclosureNetLossPerShare 26 false false R27.htm 40101 - Disclosure - Nature of Business and Liquidity (Details) Sheet http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails Nature of Business and Liquidity (Details) Details http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity 27 false false R28.htm 40301 - Disclosure - Fair Value Measurements (Details) Sheet http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://annovisbio.com/role/DisclosureFairValueMeasurementsTables 28 false false R29.htm 40401 - Disclosure - Grant Receivable (Details) Sheet http://annovisbio.com/role/DisclosureGrantReceivableDetails Grant Receivable (Details) Details http://annovisbio.com/role/DisclosureGrantReceivable 29 false false R30.htm 40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) Details http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables 30 false false R31.htm 40601 - Disclosure - Accrued Expenses (Details) Sheet http://annovisbio.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://annovisbio.com/role/DisclosureAccruedExpensesTables 31 false false R32.htm 40701 - Disclosure - Convertible Promissory Notes (Details) Notes http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails Convertible Promissory Notes (Details) Details http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes 32 false false R33.htm 40801 - Disclosure - Commitments and Contingencies - Leases (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails Commitments and Contingencies - Leases (Details) Details 33 false false R34.htm 40802 - Disclosure - Commitments and Contingencies - License Agreement (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails Commitments and Contingencies - License Agreement (Details) Details 34 false false R35.htm 40803 - Disclosure - Commitments and Contingencies - Employment Agreements and Litigation (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndLitigationDetails Commitments and Contingencies - Employment Agreements and Litigation (Details) Details 35 false false R36.htm 40901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details) Sheet http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details) Details 36 false false R37.htm 40902 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details) Sheet http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details) Details http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity 37 false false R38.htm 41001 - Disclosure - Share-Based Compensation (Details) Sheet http://annovisbio.com/role/DisclosureShareBasedCompensationDetails Share-Based Compensation (Details) Details http://annovisbio.com/role/DisclosureShareBasedCompensation 38 false false R39.htm 41101 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details) Sheet http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails Net Loss Per Share - Basic and diluted net loss per share (Details) Details 39 false false R40.htm 41102 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details) Sheet http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails Net Loss Per Share - Potential shares excluded from calculation (Details) Details 40 false false R41.htm 41201 - Disclosure - Income Taxes (Details) Sheet http://annovisbio.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://annovisbio.com/role/DisclosureIncomeTaxes 41 false false R42.htm 41301 - Disclosure - Related-Party Transactions (Details) Sheet http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails Related-Party Transactions (Details) Details http://annovisbio.com/role/DisclosureRelatedPartyTransactions 42 false false All Reports Book All Reports anvs-20210930x10q.htm anvs-20210930.xsd anvs-20210930_cal.xml anvs-20210930_def.xml anvs-20210930_lab.xml anvs-20210930_pre.xml anvs-20210930xex31d1.htm anvs-20210930xex31d2.htm anvs-20210930xex32d1.htm anvs-20210930xex32d2.htm http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true true JSON 60 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "anvs-20210930x10q.htm": { "axisCustom": 0, "axisStandard": 16, "contextCount": 109, "dts": { "calculationLink": { "local": [ "anvs-20210930_cal.xml" ] }, "definitionLink": { "local": [ "anvs-20210930_def.xml" ] }, "inline": { "local": [ "anvs-20210930x10q.htm" ] }, "labelLink": { "local": [ "anvs-20210930_lab.xml" ] }, "presentationLink": { "local": [ "anvs-20210930_pre.xml" ] }, "schema": { "local": [ "anvs-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 304, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 29, "http://xbrl.sec.gov/dei/2021": 7, "total": 36 }, "keyCustom": 34, "keyStandard": 216, "memberCustom": 12, "memberStandard": 12, "nsprefix": "anvs", "nsuri": "http://annovisbio.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://annovisbio.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Fair Value Measurements", "role": "http://annovisbio.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "anvs:GrantsReceivableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Grant Receivable", "role": "http://annovisbio.com/role/DisclosureGrantReceivable", "shortName": "Grant Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "anvs:GrantsReceivableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Prepaid Expenses and Other Current Assets", "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Accrued Expenses", "role": "http://annovisbio.com/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Convertible Promissory Notes", "role": "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes", "shortName": "Convertible Promissory Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Commitments and Contingencies", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity", "role": "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity", "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Share-Based Compensation", "role": "http://annovisbio.com/role/DisclosureShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Net Loss Per Share", "role": "http://annovisbio.com/role/DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Income Taxes", "role": "http://annovisbio.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NgQdX91_l0KOJ90hXRe-OQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Balance Sheets", "role": "http://annovisbio.com/role/StatementBalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NgQdX91_l0KOJ90hXRe-OQ", "decimals": "0", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Related-Party Transactions", "role": "http://annovisbio.com/role/DisclosureRelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Subsequent Events", "role": "http://annovisbio.com/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Fair Value Measurements (Tables)", "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Accrued Expenses (Tables)", "role": "http://annovisbio.com/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Net Loss Per Share (Tables)", "role": "http://annovisbio.com/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NgQdX91_l0KOJ90hXRe-OQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Nature of Business and Liquidity (Details)", "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "shortName": "Nature of Business and Liquidity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_InitialPublicOfferingAndOverAllotmentOptionMember_DCpYzSsODU6cSEK7Rp5eZA", "decimals": "2", "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_JeJVoB5EqUyTWorwM9o-9Q", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NgQdX91_l0KOJ90hXRe-OQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Fair Value Measurements (Details)", "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vIi5gWa-wUWbMgS0RunF9Q", "decimals": "0", "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_OnhfgpxheE-pIdLd5fEObg", "decimals": "0", "first": true, "lang": null, "name": "anvs:IncomeFromGrants", "reportCount": 1, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Grant Receivable (Details)", "role": "http://annovisbio.com/role/DisclosureGrantReceivableDetails", "shortName": "Grant Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": "0", "lang": null, "name": "anvs:UnreimbursedEligibleCostsIncurredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NgQdX91_l0KOJ90hXRe-OQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_JeJVoB5EqUyTWorwM9o-9Q", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Balance Sheets (Parenthetical)", "role": "http://annovisbio.com/role/StatementBalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_12_31_2020_4Uyzaw7K106jKYm0Y2MN-g", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_fDnaXZaRIUKcIEUJ4UxSaQ", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NgQdX91_l0KOJ90hXRe-OQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NgQdX91_l0KOJ90hXRe-OQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NgQdX91_l0KOJ90hXRe-OQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Accrued Expenses (Details)", "role": "http://annovisbio.com/role/DisclosureAccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NgQdX91_l0KOJ90hXRe-OQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OzVyOZduu0muzrRaaA-U1Q", "decimals": "INF", "first": true, "lang": null, "name": "anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes", "reportCount": 1, "unitRef": "Unit_Standard_shares_fDnaXZaRIUKcIEUJ4UxSaQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Convertible Promissory Notes (Details)", "role": "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "shortName": "Convertible Promissory Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_hgPXwR79RE22ALkLWqLRdA", "decimals": "2", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_kXFSXJCq-02-cLGm8iMYnA", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_cJJL4o_CUEyTt4bTOnLDQw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Commitments and Contingencies - Leases (Details)", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails", "shortName": "Commitments and Contingencies - Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_cJJL4o_CUEyTt4bTOnLDQw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NgQdX91_l0KOJ90hXRe-OQ", "decimals": "0", "first": true, "lang": null, "name": "anvs:AccruedLicensePaymentsCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Commitments and Contingencies - License Agreement (Details)", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "shortName": "Commitments and Contingencies - License Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_11_1_2008_To_11_30_2008_srt_CounterpartyNameAxis_anvs_HorizonTherapeuticsPlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_xf_4Esb3ME6oII-EdVnR7A", "decimals": "0", "lang": null, "name": "anvs:LicenseAgreementMinimumAnnualCommitment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_cJJL4o_CUEyTt4bTOnLDQw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_lawsuit_ZAQ_PuaG8kSI88VjfIhaoQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - Commitments and Contingencies - Employment Agreements and Litigation (Details)", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndLitigationDetails", "shortName": "Commitments and Contingencies - Employment Agreements and Litigation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_cJJL4o_CUEyTt4bTOnLDQw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_lawsuit_ZAQ_PuaG8kSI88VjfIhaoQ", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_1_31_2020_LbsDCz9d_kaexjVwzaxDmw", "decimals": "INF", "first": true, "lang": null, "name": "anvs:NumberOfClassesOfStockDesignated", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_NY7xgDZYFU-RTnQk3yq17w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)", "role": "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_1_31_2020_LbsDCz9d_kaexjVwzaxDmw", "decimals": "INF", "first": true, "lang": null, "name": "anvs:NumberOfClassesOfStockDesignated", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_NY7xgDZYFU-RTnQk3yq17w", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_86SgTvtKtUyrjJHlylik0A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Unit_Standard_shares_fDnaXZaRIUKcIEUJ4UxSaQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details)", "role": "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails", "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_86SgTvtKtUyrjJHlylik0A", "decimals": null, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NgQdX91_l0KOJ90hXRe-OQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_fDnaXZaRIUKcIEUJ4UxSaQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Share-Based Compensation (Details)", "role": "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails", "shortName": "Share-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_12_31_2020_4Uyzaw7K106jKYm0Y2MN-g", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_fDnaXZaRIUKcIEUJ4UxSaQ", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_cJJL4o_CUEyTt4bTOnLDQw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)", "role": "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "shortName": "Net Loss Per Share - Basic and diluted net loss per share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_cJJL4o_CUEyTt4bTOnLDQw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Statements of Operations", "role": "http://annovisbio.com/role/StatementStatementsOfOperations", "shortName": "Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_cJJL4o_CUEyTt4bTOnLDQw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_b7-za-pz_kCrhiB3RPxhyA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_fDnaXZaRIUKcIEUJ4UxSaQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)", "role": "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails", "shortName": "Net Loss Per Share - Potential shares excluded from calculation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_b7-za-pz_kCrhiB3RPxhyA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_fDnaXZaRIUKcIEUJ4UxSaQ", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_cJJL4o_CUEyTt4bTOnLDQw", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Income Taxes (Details)", "role": "http://annovisbio.com/role/DisclosureIncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OzVyOZduu0muzrRaaA-U1Q", "decimals": "INF", "first": true, "lang": null, "name": "anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes", "reportCount": 1, "unitRef": "Unit_Standard_shares_fDnaXZaRIUKcIEUJ4UxSaQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Related-Party Transactions (Details)", "role": "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails", "shortName": "Related-Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_3_1_2019_To_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_ZWNmCWZQL0yWOIMJP_Katw", "decimals": "INF", "lang": null, "name": "anvs:RelatedPartyTransactionNumberOfCompanyDirectors", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_NY7xgDZYFU-RTnQk3yq17w", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_7688x9oCYU6p1pjyVNEOfA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Statements of Changes in Redeemable Convertible Preferred Stock", "role": "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock", "shortName": "Statements of Changes in Redeemable Convertible Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_7688x9oCYU6p1pjyVNEOfA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ostk2jgybk2fQJaAv66xrQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00301 - Statement - Statements of Changes in Stockholders' Equity (Deficit)", "role": "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit", "shortName": "Statements of Changes in Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OzVyOZduu0muzrRaaA-U1Q", "decimals": "0", "lang": null, "name": "anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Statements of Cash Flows", "role": "http://annovisbio.com/role/StatementStatementsOfCashFlows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vISBGN_-VkKn-mfGEUDhcQ", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Nature of Business and Liquidity", "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity", "shortName": "Nature of Business and Liquidity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_Wu_xFPlGt0GOMkP0vnI18A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 25, "tag": { "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accrued Liabilities and Interest, and Employee-Related Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "anvs_AccruedLicensePaymentsCurrent": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "order": 3.0, "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued license payments.", "label": "Accrued License Payments, Current", "terseLabel": "Accrued license payments" } } }, "localname": "AccruedLicensePaymentsCurrent", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails", "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "anvs_CommonStockAndPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pertaining to both common stock and preferred stock.", "label": "Common Stock And Preferred Stock [Member]" } } }, "localname": "CommonStockAndPreferredStockMember", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "domainItemType" }, "anvs_CommonStockAndPreferredStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum number of shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock And Preferred Stock, Shares Authorized", "terseLabel": "Number of common and preferred shares authorized" } } }, "localname": "CommonStockAndPreferredStockSharesAuthorized", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the conversion of convertible promissory notes, including embedded derivative, to common stock", "label": "Conversion of Convertible Promissory Notes, Including Embedded Derivative, to Common Stock", "verboseLabel": "Conversion of convertible promissory notes, including embedded derivative, to common stock" } } }, "localname": "ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In the conversion of promissory notes to common shares, the percentage discount to the initial offering price of shares issued in the IPO.", "label": "Conversion Of Convertible Securities, Convertible Promissory Notes, Percentage of Discount To Initial Public Offering Price", "terseLabel": "Percentage of discount to the initial offering price of shares issued in the IPO" } } }, "localname": "ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "percentItemType" }, "anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the conversion of redeemable convertible preferred stock to common stock.", "label": "Conversion of Redeemable Convertible Preferred Stock to Common Stock", "verboseLabel": "Conversion of redeemable convertible preferred stock to common stock" } } }, "localname": "ConversionOfRedeemableConvertiblePreferredStockToCommonStock", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "anvs_ConversionOfWarrantsNumberOfWarrantsConverted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants converted in a noncash (or part noncash) transaction.", "label": "Conversion of Warrants, Number of Warrants Converted", "terseLabel": "Number of warrants converted in a non-cash transaction" } } }, "localname": "ConversionOfWarrantsNumberOfWarrantsConverted", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "anvs_CumulativeNumberOfMilestonesAchieved": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The cumulative number of milestones achieved.", "label": "Cumulative Number of Milestones Achieved", "terseLabel": "Number of milestones achieved" } } }, "localname": "CumulativeNumberOfMilestonesAchieved", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid Expenses, and Other Assets Disclosure [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Earnings Per Share, Basic and Diluted, Denominator [Abstract]", "terseLabel": "Denominator" } } }, "localname": "EarningsPerShareBasicAndDilutedDenominatorAbstract", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Earnings Per Share, Basic and Diluted, Numerator [Abstract]", "terseLabel": "Numerator" } } }, "localname": "EarningsPerShareBasicAndDilutedNumeratorAbstract", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "anvs_EquityIncentivePlan2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Company's 2019 Equity Incentive Plan.", "label": "2019 Plan" } } }, "localname": "EquityIncentivePlan2019Member", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "anvs_GrantAwardRemainingAmountAvailable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remining balance of funds available under a grant award.", "label": "Grant Award, Remaining Amount Available", "terseLabel": "Remining funds available" } } }, "localname": "GrantAwardRemainingAmountAvailable", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "monetaryItemType" }, "anvs_GrantIncomePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for grant income.", "label": "Grant Income [Policy Text Block]", "terseLabel": "Grant Income" } } }, "localname": "GrantIncomePolicyTextBlock", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "anvs_GrantsReceivableDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available", "label": "Grant Receivable" } } }, "localname": "GrantsReceivableDisclosureAbstract", "nsuri": "http://annovisbio.com/20210930", "xbrltype": "stringItemType" }, "anvs_GrantsReceivableDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for grants receivables.", "label": "Grants Receivable Disclosure [Text Block]", "terseLabel": "Grant Receivable" } } }, "localname": "GrantsReceivableDisclosureTextBlock", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivable" ], "xbrltype": "textBlockItemType" }, "anvs_GrantsReceivableNoticeOfAwardAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of grant awarded.", "label": "Grants Receivable, Notice of Award Amount", "terseLabel": "Notice of Award, grant amount" } } }, "localname": "GrantsReceivableNoticeOfAwardAmount", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "monetaryItemType" }, "anvs_HorizonTherapeuticsPlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Horizon Therapeutics, PLC.", "label": "Horizon Therapeutics, PLC" } } }, "localname": "HorizonTherapeuticsPlcMember", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "anvs_IncomeFromGrants": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Outside the scope of Topic 606.", "label": "Income from Grants", "terseLabel": "Grant income" } } }, "localname": "IncomeFromGrants", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "anvs_IncreaseDecreaseInGrantsReceivable": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in grants receivable.", "label": "Increase (Decrease) in Grants Receivable", "negatedLabel": "Grant receivable" } } }, "localname": "IncreaseDecreaseInGrantsReceivable", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "anvs_InitialPublicOfferingAndOverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public and right given to the underwriter to sell additional shares over the initial allotment.", "label": "IPO and Over-Allotment Option" } } }, "localname": "InitialPublicOfferingAndOverAllotmentOptionMember", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "domainItemType" }, "anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for issuance costs associated with equity issuances.", "label": "Issuance Costs Associated with Equity Issuances [Policy Text Block]", "terseLabel": "Issuance Costs Associated with Equity Issuances" } } }, "localname": "IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "anvs_LicenseAgreementMinimumAnnualCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount of annual commitment under the terms of a license agreement.", "label": "License Agreement, Minimum Annual Commitment", "terseLabel": "Minimum annual commitment" } } }, "localname": "LicenseAgreementMinimumAnnualCommitment", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of advance notice required to terminate the license agreement.", "label": "License Agreement, Period of Advance Notice of Termination", "terseLabel": "Period for advance notice of termination" } } }, "localname": "LicenseAgreementPeriodOfAdvanceNoticeOfTermination", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "durationItemType" }, "anvs_LicenseAgreementTermsAmendedMay2012Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements, as amended May 2012, under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Amended License Agreement" } } }, "localname": "LicenseAgreementTermsAmendedMay2012Member", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "anvs_LicenseAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "License Agreements" } } }, "localname": "LicenseAgreementsAbstract", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "anvs_MaximumAggregateSeverancePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum aggregate severance payments payable to executive officers under the terms of employment agreements.", "label": "Maximum Aggregate Severance Payments", "terseLabel": "Maximum aggregate severance payments" } } }, "localname": "MaximumAggregateSeverancePayments", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndLitigationDetails" ], "xbrltype": "monetaryItemType" }, "anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the National Institute on Aging of the National Institutes of Health.", "label": "NIH" } } }, "localname": "NationalInstituteOnAgingOfNationalInstitutesOfHealthMember", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "domainItemType" }, "anvs_NatureOfBusinessAndLiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Nature of Business and Liquidity [Abstract]", "terseLabel": "Nature of Business and Liquidity" } } }, "localname": "NatureOfBusinessAndLiquidityAbstract", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "stringItemType" }, "anvs_NumberOfClassesOfStockDesignated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of classes of stock designated.", "label": "Number of classes of stock designated", "terseLabel": "Number of classes of stock designated" } } }, "localname": "NumberOfClassesOfStockDesignated", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "integerItemType" }, "anvs_NumberOfVotesForEachShareOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of vote for each share of common stock.", "label": "Number of Votes for Each Share of Common Stock", "terseLabel": "Number of vote for each share of common stock" } } }, "localname": "NumberOfVotesForEachShareOfCommonStock", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "integerItemType" }, "anvs_PercentageOfExercisePriceToShareOfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of exercise price to the share offering price.", "label": "Percentage of Exercise Price to the Share Offering Price", "terseLabel": "Percentage of exercise price to the share offering price" } } }, "localname": "PercentageOfExercisePriceToShareOfferingPrice", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "percentItemType" }, "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.", "label": "Prepaid Expense, Security Deposits, and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "anvs_PreviousPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to previous plans.", "label": "Previous Plans" } } }, "localname": "PreviousPlansMember", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "anvs_ProceedsFromGrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from grants.", "label": "Proceeds from Grants", "terseLabel": "Proceeds from grants" } } }, "localname": "ProceedsFromGrants", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "monetaryItemType" }, "anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the conversion of promissory notes to common stock as a result of the Company's closing of an initial public offering.", "label": "Conversion of promissory notes to common stock" } } }, "localname": "RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Convertible promissory notes issued by the Company and purchased by related parties.", "label": "Issuance of convertible promissory notes to related parties" } } }, "localname": "RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "anvs_RelatedPartyTransactionNumberOfCompanyDirectors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of Company directors who purchased convertible promissory notes issued by the Company.", "label": "Related Party Transaction, Number Of Company Directors", "terseLabel": "Number of directors who purchased convertible promissory notes issued by the Company" } } }, "localname": "RelatedPartyTransactionNumberOfCompanyDirectors", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "integerItemType" }, "anvs_SecondaryPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secondary sale of stock.", "label": "Secondary Public Offering" } } }, "localname": "SecondaryPublicOfferingMember", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "domainItemType" }, "anvs_Series1RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A-1 Redeemable convertible preferred stock.", "label": "Series A-1 Redeemable convertible preferred stock" } } }, "localname": "Series1RedeemableConvertiblePreferredStockMember", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "domainItemType" }, "anvs_SeriesaRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Redeemable convertible preferred stock.", "label": "Series A Redeemable convertible preferred stock" } } }, "localname": "SeriesaRedeemableConvertiblePreferredStockMember", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "domainItemType" }, "anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible notes.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Notes", "terseLabel": "Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering, shares", "verboseLabel": "Number of common shares issued upon conversion of notes" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleNotes", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible preferred stock.", "label": "Stock Issued During Period, Shares, Conversion Of Convertible Securities, Preferred Stock", "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares", "verboseLabel": "Number of shares issued for the conversion of redeemable convertible preferred stock" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "anvs_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Shares, Warrants Exercised", "terseLabel": "Exercise of warrants, shares", "verboseLabel": "Shares issued upon exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of stock issued during the period upon the conversion of convertible promissory notes.", "label": "Stock Issued During Period, Value, Conversion Of Convertible Securities, Convertible Promissory Notes", "terseLabel": "Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of stock issued during the period upon the conversion of convertible preferred stock.", "label": "Stock Issued During Period, Value, Conversion Of Convertible Securities, Preferred Stock", "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "anvs_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Value, Warrants Exercised", "terseLabel": "Exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "anvs_TemporaryEquityConversionOfPreferredStockToCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Conversion of redeemable convertible preferred stock to common stock.", "label": "Temporary Equity, Conversion of Preferred Stock to Common Stock", "negatedLabel": "Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering" } } }, "localname": "TemporaryEquityConversionOfPreferredStockToCommonStock", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "monetaryItemType" }, "anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of redeemable convertible preferred stock to common stock, shares.", "label": "Temporary Equity, Shares, Conversion of Preferred Stock to Common Stock", "negatedLabel": "Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares", "verboseLabel": "Conversion of redeemable convertible preferred stock to common stock, shares" } } }, "localname": "TemporaryEquitySharesConversionOfPreferredStockToCommonStock", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "sharesItemType" }, "anvs_UnderwritersWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Underwriters warrants.", "label": "Underwriters warrants" } } }, "localname": "UnderwritersWarrantsMember", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "domainItemType" }, "anvs_UnreimbursedEligibleCostsIncurredDuringPeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of unreimbursed eligible costs incurred during the period.", "label": "Unreimbursed Eligible Costs Incurred During the Period", "terseLabel": "Unreimbursed, eligible costs incurred under the grant" } } }, "localname": "UnreimbursedEligibleCostsIncurredDuringPeriod", "nsuri": "http://annovisbio.com/20210930", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r37", "r39", "r74", "r75", "r165", "r201" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "label": "Directors" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "label": "Executive Officers" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndLitigationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r38", "r39", "r74", "r75", "r165", "r201" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r134", "r324" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndLitigationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndLitigationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r24", "r330" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r9", "r10", "r27" ], "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "order": 2.0, "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional and clinical fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r16", "r258", "r330" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r78", "r79", "r80", "r255", "r256", "r257", "r293" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Share based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r214", "r221" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedLabel": "Issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r52", "r60", "r184", "r313" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r49", "r60", "r184", "r315" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of deferred financing fees" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Net Loss Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r71", "r120", "r123", "r129", "r136", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r284", "r288", "r305", "r328", "r330", "r351", "r359" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r36", "r71", "r136", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r284", "r288", "r305", "r328", "r330" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r238", "r253" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "verboseLabel": "Basis of Presentation of Interim Unaudited Financial Statements" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r21", "r62" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents, Carrying Value" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents, Fair Value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r63" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r56", "r62", "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of year", "periodStartLabel": "Cash and cash equivalents, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r56", "r306" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r68", "r71", "r93", "r94", "r95", "r97", "r99", "r107", "r108", "r109", "r136", "r149", "r153", "r154", "r155", "r158", "r159", "r198", "r199", "r203", "r207", "r305", "r379" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Redeemable Convertible Preferred Stock and Stockholders' Equity" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r222", "r237" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Warrants" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of warrants issued" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r222", "r237" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Grant Receivable" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r31", "r145", "r353", "r362" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies.", "terseLabel": "Commitments and contingencies (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r142", "r143", "r144", "r147", "r372" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r78", "r79", "r293" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Number of common shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r214" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r330" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock - $0.0001 par value, 35,000,000 shares authorized, and 6,947,120 and 6,891,608 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r160", "r161", "r162", "r164", "r174", "r175", "r176", "r180", "r181", "r182", "r183", "r184", "r190", "r191", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible promissory notes" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes." } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r67", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r178", "r185", "r186", "r188", "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Convertible Promissory Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r161", "r190", "r191", "r314", "r316", "r317" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r29", "r189", "r314", "r316" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r29", "r162" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Convertible Promissory Notes" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r30", "r70", "r76", "r161", "r162", "r163", "r164", "r165", "r166", "r168", "r174", "r175", "r176", "r177", "r179", "r180", "r181", "r182", "r183", "r184", "r187", "r190", "r191", "r192", "r193", "r215", "r218", "r219", "r220", "r313", "r314", "r316", "r317", "r358" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangements [Abstract]", "terseLabel": "Employment Agreements" } } }, "localname": "DeferredCompensationArrangementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of prepaid expenses and other current assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r48", "r83", "r84", "r85", "r86", "r87", "r91", "r93", "r97", "r98", "r99", "r103", "r104", "r294", "r295", "r356", "r364" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic loss per common share", "verboseLabel": "Net loss per share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r48", "r83", "r84", "r85", "r86", "r87", "r93", "r97", "r98", "r99", "r103", "r104", "r294", "r295", "r356", "r364" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted loss per common share", "verboseLabel": "Net loss per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r100", "r101" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Net Income (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r100", "r101", "r102", "r105" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "order": 1.0, "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails", "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r43", "r44", "r45", "r78", "r79", "r80", "r82", "r88", "r90", "r106", "r137", "r214", "r221", "r255", "r256", "r257", "r273", "r274", "r293", "r307", "r308", "r309", "r310", "r311", "r312", "r367", "r368", "r369", "r382" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r176", "r190", "r191", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r236", "r297", "r333", "r334", "r335" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r296", "r297", "r299", "r300", "r302" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r176", "r228", "r229", "r234", "r236", "r297", "r333" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r176", "r190", "r191", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r236", "r333", "r334", "r335" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r50" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrantsReceivableCurrent": { "auth_ref": [ "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Grants Receivable, Current", "terseLabel": "Grant receivable" } } }, "localname": "GrantsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r46", "r120", "r122", "r125", "r128", "r130", "r350", "r354", "r357", "r365" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r72", "r267", "r268", "r271", "r275", "r277", "r279", "r280", "r281" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r73", "r89", "r90", "r119", "r266", "r276", "r278", "r366" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r42", "r264", "r265", "r268", "r269", "r270", "r272" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r59" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r59" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r59" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Changes in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Changes in Redeemable Convertible Preferred Stock" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r54", "r57", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash payments for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Leases" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r26", "r71", "r124", "r136", "r149", "r150", "r151", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r285", "r288", "r289", "r305", "r328", "r329" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r71", "r136", "r305", "r330", "r352", "r361" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r28", "r71", "r136", "r149", "r150", "r151", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r285", "r288", "r289", "r305", "r328", "r329", "r330" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r30", "r148" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyClaimsDismissedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of claims dismissed.", "label": "Loss Contingency, Claims Dismissed, Number", "terseLabel": "Number of complaints dismissed during the period" } } }, "localname": "LossContingencyClaimsDismissedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndLitigationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss Contingency, Information about Litigation Matters [Abstract]", "terseLabel": "Litigation" } } }, "localname": "LossContingencyInformationAboutLitigationMattersAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Number of new claims filed" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndLitigationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r56" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r56", "r58", "r61" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r40", "r41", "r45", "r47", "r61", "r71", "r81", "r83", "r84", "r85", "r86", "r89", "r90", "r96", "r120", "r122", "r125", "r128", "r130", "r136", "r149", "r150", "r151", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r295", "r305", "r355", "r363" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r51" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r120", "r122", "r125", "r128", "r130" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rental expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Business and Liquidity" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r292" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Business and Liquidity" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r4", "r7", "r139" ], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r238", "r253" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14", "r198" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Number of preferred shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14", "r198" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14", "r330" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock - $0.0001 par value, 2,000,000 shares authorized, and 0 shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r5", "r7", "r138", "r139" ], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "verboseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r53" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs", "verboseLabel": "Gross proceeds from issuance of common shares" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r53", "r254" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r40", "r41", "r45", "r55", "r71", "r81", "r89", "r90", "r120", "r122", "r125", "r128", "r130", "r136", "r149", "r150", "r151", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r283", "r286", "r287", "r290", "r291", "r295", "r305", "r357" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.", "label": "Redeemable convertible preferred stock" } } }, "localname": "RedeemableConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r235", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r235", "r321", "r322", "r325" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r235", "r321", "r325", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r319", "r320", "r322", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r261", "r336", "r373" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r22", "r140", "r141", "r373" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r221", "r258", "r330", "r360", "r370", "r371" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r78", "r79", "r80", "r82", "r88", "r90", "r137", "r255", "r256", "r257", "r273", "r274", "r293", "r367", "r369" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r117", "r118", "r121", "r126", "r127", "r131", "r132", "r133", "r224", "r225", "r337" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds from issuance of common shares" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of shares excluded from the computation of diluted weighted-average shares outstanding" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r323", "r325" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r238", "r253" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r32", "r68", "r107", "r108", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r203", "r207", "r212", "r215", "r216", "r217", "r218", "r219", "r220", "r221" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r35" ], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r59" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense", "verboseLabel": "Share-based compensation expense, including stock issued to consultants and advisors" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Dividend yield (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r244", "r253" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "terseLabel": "Options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Options, vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r237", "r242" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r238", "r243" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Term of award" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r248", "r259" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r66", "r77" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r13", "r14", "r15", "r68", "r71", "r93", "r94", "r95", "r97", "r99", "r107", "r108", "r109", "r136", "r149", "r153", "r154", "r155", "r158", "r159", "r198", "r199", "r203", "r207", "r214", "r305", "r379" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r33", "r43", "r44", "r45", "r78", "r79", "r80", "r82", "r88", "r90", "r106", "r137", "r214", "r221", "r255", "r256", "r257", "r273", "r274", "r293", "r307", "r308", "r309", "r310", "r311", "r312", "r367", "r368", "r369", "r382" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r78", "r79", "r80", "r106", "r337" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Issuance of common stock to consultants and advisors, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r14", "r15", "r214", "r221" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock in initial public offering, net of issuance costs (in shares)", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r15", "r214", "r221", "r245" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "verboseLabel": "Exercise of stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Issuance of common stock to consultants and advisors" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r14", "r15", "r214", "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in initial public offering, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r33", "r214", "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r18", "r19", "r71", "r135", "r136", "r305", "r330" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable Convertible Preferred Stock and Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r69", "r199", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r221", "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Redeemable Convertible Preferred Stock and Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r331", "r332" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental disclosure of non-cash financing activities:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r149", "r153", "r154", "r155", "r158", "r159" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "sharesItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r60" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "negatedLabel": "Change in fair value of derivative liability", "terseLabel": "Change in fair value of derivative liability" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r110", "r111", "r112", "r113", "r114", "r115", "r116" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrant term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r92", "r99" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares outstanding, diluted", "verboseLabel": "Weighted-average common shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r91", "r99" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding, basic", "verboseLabel": "Weighted-average common shares outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r327": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r332": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r374": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r375": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r376": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r377": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r378": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r379": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r380": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r381": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" } }, "version": "2.1" } ZIP 61 0001558370-21-014220-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-21-014220-xbrl.zip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end